|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
EXP |
ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased activity of ACP5 protein] |
CTD |
PMID:27387537 |
|
NCBI chr 8:23,142,733...23,149,067
Ensembl chr 8:23,142,734...23,148,396
|
|
G |
Ar |
androgen receptor |
increases degradation multiple interactions |
ISO |
ginsenoside Rg3 results in increased degradation of AR protein ginsenoside Rg3 inhibits the reaction [Testosterone results in increased expression of AR protein] |
CTD |
PMID:22101440 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased expression of BAX protein] |
CTD |
PMID:26427350 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in increased expression of BCL2 protein] |
CTD |
PMID:26427350 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO |
[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]] |
CTD |
PMID:24394491 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
EXP |
ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BGLAP protein] |
CTD |
PMID:27387537 |
|
NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of BIRC5 mRNA; ginsenoside Rg3 results in decreased expression of BIRC5 protein |
CTD |
PMID:19778801 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
EXP |
ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMP2 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMP2 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]] |
CTD |
PMID:27387537 |
|
NCBI chr 3:126,335,963...126,346,771
Ensembl chr 3:126,335,863...126,346,318
|
|
G |
Bmpr1a |
bone morphogenetic protein receptor type 1A |
multiple interactions |
EXP |
ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMPR1A mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMPR1A protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]] |
CTD |
PMID:27387537 |
|
NCBI chr16:10,758,278...10,852,170
Ensembl chr16:10,758,527...10,802,512
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
ginsenoside Rg3 results in increased cleavage of CASP3 protein ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of CASP3 protein] |
CTD |
PMID:22101440 PMID:26427350 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of CASP8 protein] |
CTD |
PMID:26427350 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of CASP9 protein] |
CTD |
PMID:26427350 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein] |
CTD |
PMID:24793912 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
EGF protein promotes the reaction [ginsenoside Rg3 affects the phosphorylation of EGFR protein]; ginsenoside Rg3 inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]] |
CTD |
PMID:25824408 |
|
NCBI chr 2:68,820,616...68,895,537
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions affects phosphorylation |
ISO |
EGF protein promotes the reaction [ginsenoside Rg3 affects the phosphorylation of EGFR protein]; ginsenoside Rg3 inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]]; ginsenoside Rg3 results in decreased expression of and affects the localization of EGFR protein |
CTD |
PMID:25824408 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Fut4 |
fucosyltransferase 4 |
multiple interactions decreases expression |
ISO |
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in increased expression of FUT4 protein] ginsenoside Rg3 results in decreased expression of FUT4 protein |
CTD |
PMID:26427350 |
|
NCBI chr 8:13,258,768...13,262,729
Ensembl chr 8:13,258,768...13,262,729
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
multiple interactions decreases expression |
ISO |
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in increased expression of HSF1 protein] ginsenoside Rg3 results in decreased expression of HSF1 protein |
CTD |
PMID:26427350 |
|
NCBI chr 7:117,538,523...117,565,478
Ensembl chr 7:117,538,523...117,565,478
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
EXP |
ginsenoside Rg3 results in increased expression of IL1B protein |
CTD |
PMID:14534150 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
ISO |
ginsenoside Rg3 results in increased expression of MAP2 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 9:73,204,753...73,462,965
Ensembl chr 9:73,319,710...73,462,972
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of MMP2 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of MMP2 mRNA] |
CTD |
PMID:24793912 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions increases activity |
EXP |
[ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of NFKB1 protein ginsenoside Rg3 results in increased activity of NFKB1 protein |
CTD |
PMID:14534150 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP |
[ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of NFKB1 protein; [ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of RELA protein |
CTD |
PMID:14534150 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nog |
noggin |
multiple interactions |
EXP |
NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 protein]] |
CTD |
PMID:27387537 |
|
NCBI chr10:76,811,759...76,813,386
Ensembl chr10:76,811,759...76,813,386
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
EXP |
Staurosporine inhibits the reaction [ginsenoside Rg3 results in increased expression of NOS2 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [ginsenoside Rg3 results in increased expression of NOS2 protein] ginsenoside Rg3 results in increased expression of NOS2 mRNA |
CTD |
PMID:14534150 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] results in decreased susceptibility to Chlorodiphenyl (54% Chlorine)]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] results in decreased susceptibility to [Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] [Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of NTRK2 protein modified form]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] results in decreased susceptibility to Chlorodiphenyl (54% Chlorine)]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] results in decreased susceptibility to [Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] |
CTD |
PMID:24394491 |
|
NCBI chr17:5,934,651...6,245,778
Ensembl chr17:5,933,729...6,244,676
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
ginsenoside Rg3 results in increased cleavage of PARP1 protein ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased cleavage of PARP1 protein]; ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of PARP1 protein] |
CTD |
PMID:22101440 PMID:24793912 PMID:26427350 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression |
EXP |
ginsenoside Rg3 results in increased expression of PCK1 mRNA |
CTD |
PMID:30144466 |
|
NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
EXP |
ginsenoside Rg3 results in increased expression of PPARGC1A mRNA |
CTD |
PMID:30144466 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
[ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of RELA protein; ginsenoside Rg3 affects the localization of and results in increased activity of RELA protein |
CTD |
PMID:14534150 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
EXP |
ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]] |
CTD |
PMID:27387537 |
|
NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
|
|
G |
Sirt1 |
sirtuin 1 |
increases activity |
EXP |
ginsenoside Rg3 results in increased activity of SIRT1 protein |
CTD |
PMID:30144466 |
|
NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
|
|
G |
Slc6a2 |
solute carrier family 6 member 2 |
multiple interactions |
ISO |
[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of SLC6A2 protein] |
CTD |
PMID:24394491 |
|
NCBI chr19:15,391,682...15,431,274
Ensembl chr19:15,391,581...15,431,274
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
multiple interactions |
ISO |
[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of SLC6A3 protein] |
CTD |
PMID:24394491 |
|
NCBI chr 1:32,323,011...32,363,983
Ensembl chr 1:32,321,580...32,363,983
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions |
ISO |
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:24793912 |
|
NCBI chr18:72,550,107...72,612,078
Ensembl chr18:72,550,219...72,612,078
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
multiple interactions |
ISO |
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein] |
CTD |
PMID:24793912 |
|
NCBI chr 3:164,274,710...164,279,199
Ensembl chr 3:164,274,710...164,279,378
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased expression of SP1 protein] |
CTD |
PMID:26427350 |
|
NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased cleavage of PARP1 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of MMP2 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of MMP2 mRNA]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:24793912 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP |
ginsenoside Rg3 results in increased expression of TNF protein |
CTD |
PMID:14534150 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions |
EXP |
ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]] |
CTD |
PMID:27387537 |
|
NCBI chr 7:93,798,580...93,826,586
Ensembl chr 7:93,798,545...93,826,665
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
EXP |
ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 protein]] |
CTD |
PMID:27387537 |
|
NCBI chr15:60,482,527...60,512,704
Ensembl chr15:60,482,527...60,512,704
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of VIM protein] |
CTD |
PMID:24793912 |
|
NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
|
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
ginsenoside Rh1 results in increased expression of FOS mRNA |
CTD |
PMID:16204943 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of IL1B mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL1B mRNA] |
CTD |
PMID:16557482 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il4 |
interleukin 4 |
decreases expression |
ISO |
ginsenoside Rh1 results in decreased expression of IL4 |
CTD |
PMID:22855946 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Itga4 |
integrin subunit alpha 4 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 3:66,178,745...66,265,547
Ensembl chr 3:66,193,059...66,263,960
|
|
G |
Itgal |
integrin subunit alpha L |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 1:198,744,053...198,781,745
Ensembl chr 1:198,744,050...198,781,750
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
|
|
G |
Itgb2 |
integrin subunit beta 2 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr20:11,777,773...11,815,647
Ensembl chr20:11,777,783...11,815,647
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases activity |
ISO |
ginsenoside Rh1 results in decreased activity of JUN protein |
CTD |
PMID:22855946 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Lpl |
lipoprotein lipase |
increases secretion |
ISO |
ginsenoside Rh1 results in increased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Pgr |
progesterone receptor |
increases expression |
ISO |
ginsenoside Rh1 results in increased expression of PGR protein |
CTD |
PMID:16204943 |
|
NCBI chr 8:7,128,656...7,187,796
Ensembl chr 8:7,128,656...7,187,796
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of PTGS2 mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA] |
CTD |
PMID:16557482 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:21875580 |
|
NCBI chr13:82,355,234...82,365,323
Ensembl chr13:82,355,471...82,365,341
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
ginsenoside Rh1 results in increased expression of TFF1 mRNA |
CTD |
PMID:16204943 |
|
NCBI chr20:9,892,124...9,895,984
Ensembl chr20:9,892,124...9,895,984
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression decreases response to substance |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of SELE protein]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of TNF mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF mRNA] ginsenoside Rh1 results in decreased expression of TNF ginsenoside Rh1 results in decreased susceptibility to TNF protein |
CTD |
PMID:16557482 PMID:21875580 PMID:22855946 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
ginsenoside Rh2 results in increased expression of BAX protein |
CTD |
PMID:26482938 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of BCL2 protein |
CTD |
PMID:26482938 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Casp3 |
caspase 3 |
increases cleavage |
ISO |
ginsenoside Rh2 results in increased cleavage of CASP3 protein |
CTD |
PMID:26482938 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of CCND1 protein |
CTD |
PMID:26482938 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Hdac1 |
histone deacetylase 1 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of HDAC1 protein |
CTD |
PMID:26482938 |
|
NCBI chr 5:147,716,664...147,743,723
Ensembl chr 5:147,716,664...147,743,723
|
|
G |
Hdac2 |
histone deacetylase 2 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of HDAC2 protein |
CTD |
PMID:26482938 |
|
NCBI chr20:43,084,870...43,108,198
Ensembl chr20:43,084,870...43,108,198
|
|
G |
Hdac6 |
histone deacetylase 6 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of HDAC6 protein |
CTD |
PMID:26482938 |
|
NCBI chr X:15,295,372...15,316,673
Ensembl chr X:15,295,473...15,316,671
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside Rh2 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation |
ISO |
ginsenoside Rh2 results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:26482938 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation |
ISO |
ginsenoside Rh2 results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:26482938 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
EXP |
estriol 17-glucuronide inhibits the reaction [ABCB1 results in increased transport of estradiol-17 beta-glucuronide] |
CTD |
PMID:9794924 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
|
G |
Myl9 |
myosin light chain 9 |
multiple interactions |
EXP |
[Escin affects the susceptibility to Calcium] which results in increased phosphorylation of MYL9 protein; [Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein; Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Calcium] which results in increased phosphorylation of MYL9 protein]; Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein]; Y 27632 inhibits the reaction [[Escin affects the susceptibility to Calcium] which results in increased phosphorylation of MYL9 protein]; Y 27632 inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein] |
CTD |
PMID:29660437 |
|
NCBI chr 3:152,857,573...152,863,961
Ensembl chr 3:152,857,592...152,863,960
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
EXP |
[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased localization of RHOA protein; Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased localization of RHOA protein] |
CTD |
PMID:29660437 |
|
NCBI chr 8:117,082,440...117,116,244
Ensembl chr 8:117,106,576...117,116,167
|
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
alpha-chaconine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; alpha-chaconine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:25913072 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
alpha-chaconine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; alpha-chaconine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] |
CTD |
PMID:25913072 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
alpha-chaconine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of and affects the localization of JUN protein]; alpha-chaconine inhibits the reaction [Lipopolysaccharides results in increased expression of JUN protein modified form] |
CTD |
PMID:25913072 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Map2k7 |
mitogen activated protein kinase kinase 7 |
multiple interactions |
ISO |
alpha-chaconine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAP2K7 protein] |
CTD |
PMID:25913072 |
|
NCBI chr12:2,546,278...2,555,310
Ensembl chr12:2,548,218...2,555,164
|
|
G |
Map3k7 |
mitogen activated protein kinase kinase kinase 7 |
multiple interactions |
ISO |
alpha-chaconine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAP3K7 protein] |
CTD |
PMID:25913072 |
|
NCBI chr 5:47,183,142...47,244,424
Ensembl chr 5:47,186,558...47,244,416
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
alpha-chaconine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:25913072 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
alpha-chaconine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:25913072 |
|
NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
alpha-chaconine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; alpha-chaconine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein] |
CTD |
PMID:25913072 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
alpha-chaconine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; alpha-chaconine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein] |
CTD |
PMID:25913072 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
alpha-chaconine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; alpha-chaconine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:25913072 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions increases expression |
EXP |
asiaticoside inhibits the reaction [Rotenone results in decreased expression of BDNF mRNA] asiaticoside results in increased expression of BDNF mRNA |
CTD |
PMID:28238857 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
asiaticoside inhibits the reaction [Rotenone results in decreased activity of CAT protein] |
CTD |
PMID:28238857 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases activity |
ISO |
asiaticoside results in decreased activity of CYP2C19 protein |
CTD |
PMID:21349323 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases activity |
ISO |
asiaticoside results in decreased activity of CYP3A4 protein |
CTD |
PMID:21349323 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
EXP |
asiaticoside inhibits the reaction [Rotenone results in decreased expression of MAPK14 protein] |
CTD |
PMID:28238857 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
[asiaticoside co-treated with Rotenone] results in decreased expression of MTOR protein |
CTD |
PMID:28238857 |
|
NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
|
|
G |
Ngf |
nerve growth factor |
increases expression multiple interactions |
EXP |
asiaticoside results in increased expression of NGF protein asiaticoside inhibits the reaction [Rotenone results in decreased expression of NGF protein] |
CTD |
PMID:28238857 |
|
NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
|
|
G |
Pdpk1 |
3-phosphoinositide dependent protein kinase-1 |
multiple interactions |
EXP |
asiaticoside inhibits the reaction [Rotenone results in decreased expression of PDPK1 mRNA]; asiaticoside inhibits the reaction [Rotenone results in decreased expression of PDPK1 protein] |
CTD |
PMID:28238857 |
|
NCBI chr10:13,446,373...13,525,248
Ensembl chr10:13,451,624...13,515,448
|
|
G |
Pebp1 |
phosphatidylethanolamine binding protein 1 |
multiple interactions |
EXP |
asiaticoside inhibits the reaction [Rotenone results in increased expression of PEBP1 mRNA] |
CTD |
PMID:28238857 |
|
NCBI chr12:45,026,948...45,031,148
Ensembl chr12:45,026,886...45,031,145
|
|
G |
Pik3r6 |
phosphoinositide-3-kinase, regulatory subunit 6 |
multiple interactions |
EXP |
asiaticoside inhibits the reaction [Rotenone results in decreased expression of PIK3R6 mRNA] |
CTD |
PMID:28238857 |
|
NCBI chr10:55,085,269...55,135,069
Ensembl chr10:55,085,259...55,135,092
|
|
G |
Slc18a2 |
solute carrier family 18 member A2 |
multiple interactions |
EXP |
asiaticoside inhibits the reaction [Rotenone results in decreased expression of SLC18A2 mRNA] |
CTD |
PMID:28238857 |
|
NCBI chr 1:280,397,831...280,457,968
Ensembl chr 1:280,423,079...280,457,148
|
|
G |
Stx1a |
syntaxin 1A |
multiple interactions |
EXP |
[Rotenone co-treated with asiaticoside] results in decreased expression of STX1A mRNA |
CTD |
PMID:28238857 |
|
NCBI chr12:24,682,050...24,710,002
Ensembl chr12:24,682,041...24,710,019
|
|
G |
Synj1 |
synaptojanin 1 |
multiple interactions |
EXP |
[asiaticoside co-treated with Rotenone] results in decreased expression of SYNJ1 mRNA |
CTD |
PMID:28238857 |
|
NCBI chr11:31,105,784...31,181,573
Ensembl chr11:31,104,787...31,180,642
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
[asiaticoside co-treated with Rotenone] results in decreased expression of TH protein |
CTD |
PMID:28238857 |
|
NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
|
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Isoproterenol results in decreased expression of and results in decreased activity of ATP2A2 protein]; astragaloside A inhibits the reaction [Isoproterenol results in decreased expression of ATP2A2 mRNA] |
CTD |
PMID:17509559 |
|
NCBI chr12:39,553,903...39,603,326
Ensembl chr12:39,553,903...39,603,326
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein] |
CTD |
PMID:22278385 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcs1l |
BCS1 homolog, ubiquinol-cytochrome c reductase complex chaperone |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCS1L protein] |
CTD |
PMID:22278385 |
|
NCBI chr 9:81,868,158...81,872,201
Ensembl chr 9:81,868,265...81,872,197
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased cleavage of CASP3 protein] astragaloside A inhibits the reaction [Cisplatin results in increased expression of CASP3 protein] |
CTD |
PMID:22278385 PMID:30842369 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Cisplatin results in increased expression of GPT protein] |
CTD |
PMID:30842369 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein astragaloside A results in increased expression of HMOX1 mRNA; astragaloside A results in increased expression of HMOX1 protein |
CTD |
PMID:25422538 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Cisplatin results in increased expression of IL1B protein]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B protein] |
CTD |
PMID:25604657 PMID:30842369 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein] |
CTD |
PMID:25604657 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Taurocholic Acid results in increased activity of MPO protein] |
CTD |
PMID:25604657 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions affects localization |
ISO |
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein astragaloside A affects the localization of NFE2L2 protein |
CTD |
PMID:25422538 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA protein] |
CTD |
PMID:25604657 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nfkbib |
NFKB inhibitor beta |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB protein] |
CTD |
PMID:25604657 |
|
NCBI chr 1:86,941,073...86,948,845
Ensembl chr 1:86,941,074...86,948,845
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein] |
CTD |
PMID:30842369 |
|
NCBI chr10:45,884,324...45,918,290
Ensembl chr10:45,893,018...45,918,254
|
|
G |
Pln |
phospholamban |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Isoproterenol results in decreased phosphorylation of PLN protein] |
CTD |
PMID:17509559 |
|
NCBI chr20:34,633,157...34,642,904
Ensembl chr20:34,633,157...34,642,904
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Taurocholic Acid affects the localization of RELA protein] |
CTD |
PMID:25604657 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 protein] |
CTD |
PMID:25604657 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
astragaloside A promotes the reaction [Taurocholic Acid results in decreased expression of SOD2 protein]; astragaloside A promotes the reaction [Taurocholic Acid results in increased expression of SOD2 mRNA] |
CTD |
PMID:25604657 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Cisplatin results in increased expression of SQSTM1 protein] |
CTD |
PMID:30842369 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein] |
CTD |
PMID:25604657 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
araloside A results in decreased expression of BCL2 protein |
CTD |
PMID:31004595 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression decreases secretion |
ISO |
araloside A results in decreased expression of IL1B mRNA araloside A results in decreased secretion of IL1B protein |
CTD |
PMID:31004595 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
decreases expression decreases secretion |
ISO |
araloside A results in decreased expression of IL6 mRNA araloside A results in decreased secretion of IL6 protein |
CTD |
PMID:31004595 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases phosphorylation |
ISO |
araloside A results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:31004595 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
decreases phosphorylation |
ISO |
araloside A results in decreased phosphorylation of RELA protein |
CTD |
PMID:31004595 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
chikusetsusaponin V inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein] |
CTD |
PMID:25073091 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
chikusetsusaponin V inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein] |
CTD |
PMID:25073091 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Casp12 |
caspase 12 |
multiple interactions |
ISO |
chikusetsusaponin V inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CASP12 mRNA] |
CTD |
PMID:25073091 |
|
NCBI chr 8:2,658,892...2,686,160
Ensembl chr 8:2,659,865...2,686,160
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
chikusetsusaponin V inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HSPA5 protein] |
CTD |
PMID:25073091 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Lpl |
lipoprotein lipase |
increases secretion |
ISO |
ginsenoside Ro results in increased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
chikusetsusaponin V inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of SIRT1 protein] |
CTD |
PMID:25073091 |
|
NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
chikusetsusaponin V inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of SOD2 mRNA] |
CTD |
PMID:25073091 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
|
G |
Cdh5 |
cadherin 5 |
multiple interactions |
ISO |
Digitonin inhibits the reaction [[ETV2 protein co-treated with GATA2 protein] results in decreased expression of CDH5 protein] |
CTD |
PMID:31404653 |
|
NCBI chr19:1,025,122...1,074,333
Ensembl chr19:1,023,683...1,074,365
|
|
G |
Etv2 |
ETS variant transcription factor 2 |
multiple interactions |
ISO |
Digitonin inhibits the reaction [[ETV2 protein co-treated with GATA2 protein] results in decreased expression of CDH5 protein]; Digitonin inhibits the reaction [[ETV2 protein co-treated with GATA2 protein] results in increased expression of SPN protein] |
CTD |
PMID:31404653 |
|
NCBI chr 1:89,091,239...89,094,570
Ensembl chr 1:89,091,239...89,094,530
|
|
G |
Gata2 |
GATA binding protein 2 |
multiple interactions |
ISO |
Digitonin inhibits the reaction [[ETV2 protein co-treated with GATA2 protein] results in decreased expression of CDH5 protein]; Digitonin inhibits the reaction [[ETV2 protein co-treated with GATA2 protein] results in increased expression of SPN protein] |
CTD |
PMID:31404653 |
|
NCBI chr 4:120,129,028...120,142,490
Ensembl chr 4:120,133,713...120,142,488
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Digitonin inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
|
|
G |
Spn |
sialophorin |
multiple interactions |
ISO |
Digitonin inhibits the reaction [[ETV2 protein co-treated with GATA2 protein] results in increased expression of SPN protein] |
CTD |
PMID:31404653 |
|
NCBI chr 1:198,572,999...198,585,664
Ensembl chr 1:198,572,999...198,577,226
|
|
|
G |
Abca8 |
ATP binding cassette subfamily A member 8 |
multiple interactions |
ISO |
Digoxin inhibits the reaction [ABCA8 protein results in increased uptake of estradiol-17 beta-glucuronide] |
CTD |
PMID:12379217 |
|
NCBI chr10:98,236,919...98,308,288
Ensembl chr10:98,237,141...98,294,522
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects abundance affects uptake increases uptake multiple interactions increases export increases transport affects secretion increases expression affects binding decreases uptake affects transport |
ISO EXP |
ABCB1 gene SNP affects the abundance of Digoxin ABCB1A protein affects the uptake of Digoxin ABCB1 protein results in increased uptake of Digoxin 18alpha-glycyrrhetinic acid inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; 2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate inhibits the reaction [Digoxin results in increased expression of ABCB1 protein]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole inhibits the reaction [Digoxin results in increased expression of ABCB1 mRNA]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole inhibits the reaction [Digoxin results in increased expression of ABCB1 protein]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; [citronellal results in decreased activity of ABCB1 protein] which results in decreased export of Digoxin; [citronellol results in decreased activity of ABCB1 protein] which results in decreased export of Digoxin; [Cyclosporine binds to and results in decreased activity of ABCB1 protein] which results in decreased export of Digoxin; [Digoxin results in increased expression of ABCB1] which results in decreased susceptibility to Doxorubicin; [Elacridar binds to and results in decreased activity of ABCB1 protein] which results in decreased export of Digoxin; [Elacridar results in decreased activity of ABCB1 protein] which results in increased uptake of Digoxin; [isopropyl 5,12-hydroxypentadeca-8,10-dien-6,14-diynoate results in decreased activity of ABCB1 protein] which results in increased uptake of Digoxin; [Ketoconazole binds to and results in decreased activity of ABCB1 protein] which results in decreased export of Digoxin; [Ketoconazole results in decreased activity of ABCB1 protein] which results in increased uptake of Digoxin; [Plant Extracts results in decreased activity of ABCB1 protein] which results in decreased export of Digoxin; [valspodar results in decreased activity of ABCB1 protein] which results in decreased transport of Digoxin; [Verapamil binds to and results in decreased activity of ABCB1 protein] which results in decreased export of Digoxin; [Verapamil results in decreased activity of ABCB1 protein] which results in decreased transport of Digoxin; ABCB1 protein binds to and affects the metabolism of Digoxin; abietic acid inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; Amiodarone inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; azelastine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; benidipine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Bepridil inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; beta-pinene inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; Bisoprolol inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Capsaicin affects the reaction [ABCB1 protein results in increased export of Digoxin]; Carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; citronellal inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; citronellol inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; cucurbitacin I inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; Curcumin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; cyazofamid affects the reaction [ABCB1 protein results in increased uptake of Digoxin]; dehydroandrographolide inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; desethylamiodarone inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; desmethylazelastine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Diazinon affects the reaction [ABCB1 protein results in increased transport of Digoxin]; Digoxin inhibits the reaction [ABCB1 protein results in increased transport of quinidinium]; Diltiazem inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Doxazosin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; efonidipine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Emodin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Fusidic Acid inhibits the reaction [ABCB1 protein results in increased export of Digoxin]; gamma-terpinene inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; gingerol inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; ginsenoside F2 analog inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Glycyrrhetinic Acid inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; Itraconazole inhibits the reaction [ABCB1 protein affects the transport of Digoxin]; Ketoconazole inhibits the reaction [ABCB1 protein affects the transport of Digoxin]; Ketoconazole inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; KN 93 inhibits the reaction [Digoxin results in increased expression of ABCB1 protein]; manidipine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; mepirodipine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Nicardipine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; nilvadipine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Nisoldipine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; nobiletin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; ophiobolin A inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; Propranolol inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; rhodioloside affects the reaction [ABCB1 protein results in increased transport of Digoxin]; Rifampin promotes the reaction [ABCB1 protein results in increased transport of Digoxin]; sciadopitysin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; sinensetin analog inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; sinensetin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; spinosad inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; tangeretin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; terpinolene inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; valspodar inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Verapamil inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Verapamil inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin] Acetaminophen promotes the reaction [ABCB1 protein results in increased transport of Digoxin] ABCB1A protein results in increased uptake of Digoxin ABCB1 protein affects the secretion of Digoxin Digoxin results in increased expression of ABCB1 mRNA; Digoxin results in increased expression of ABCB1 protein Digoxin binds to ABCB1 protein ABCB1 protein results in decreased uptake of Digoxin ABCB1 gene SNP affects the transport of Digoxin; ABCB1 protein affects the transport of Digoxin |
CTD |
PMID:10527640 PMID:10562306 PMID:10617675 PMID:10997946 PMID:11231118 PMID:11895100 PMID:15276087 PMID:15856409 PMID:15890377 PMID:15969931 PMID:16221533 PMID:16671962 PMID:16674925 PMID:16904803 PMID:17365992 PMID:18385293 PMID:19505989 PMID:19647009 PMID:19958760 PMID:21240898 PMID:21311904 PMID:21321059 PMID:21341280 PMID:23104431 PMID:23976943 PMID:24380838 PMID:25844889 PMID:26888941 PMID:30790579 PMID:32003934 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
affects uptake |
ISO |
ABCB1B protein affects the uptake of Digoxin |
CTD |
PMID:10562306 |
|
NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
decreases activity |
ISO |
Digoxin results in decreased activity of ABCG2 protein |
CTD |
PMID:15365089 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Atp1a2 |
ATPase Na+/K+ transporting subunit alpha 2 |
decreases expression multiple interactions |
EXP |
Digoxin results in decreased expression of ATP1A2 mRNA N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine inhibits the reaction [Digoxin results in decreased expression of ATP1A2 mRNA] |
CTD |
PMID:19687166 |
|
NCBI chr13:90,651,682...90,676,629
Ensembl chr13:90,651,686...90,676,629
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
decreases expression multiple interactions |
EXP |
Digoxin results in decreased expression of ATP1A3 mRNA N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine inhibits the reaction [Digoxin results in decreased expression of ATP1A3 mRNA] |
CTD |
PMID:19687166 |
|
NCBI chr 1:81,852,423...81,881,565
Ensembl chr 1:81,852,429...81,881,549
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Digoxin results in decreased expression of CCL2 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression |
ISO |
Digoxin results in decreased expression of CCL4 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:70,870,926...70,886,357
Ensembl chr10:70,884,531...70,886,355
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
decreases expression |
ISO |
Digoxin results in decreased expression of CCL5 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Fancd2 |
FA complementation group D2 |
multiple interactions |
ISO |
Digoxin inhibits the reaction [Mitomycin results in increased expression of and affects the ubiquitination of FANCD2 protein] |
CTD |
PMID:24124520 |
|
NCBI chr 4:145,489,869...145,551,479
Ensembl chr 4:145,489,869...145,551,479
|
|
G |
Fanci |
FA complementation group I |
multiple interactions |
ISO |
Digoxin inhibits the reaction [Mitomycin results in increased expression of and affects the ubiquitination of FANCI protein] |
CTD |
PMID:24124520 |
|
NCBI chr 1:141,116,565...141,172,997
Ensembl chr 1:141,120,166...141,172,483
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases activity |
EXP |
Digoxin results in decreased activity of G6PD protein |
CTD |
PMID:26820767 |
|
NCBI chr X:156,274,800...156,293,935
Ensembl chr X:156,274,800...156,293,926
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression |
EXP |
Digoxin results in increased expression of GFAP mRNA |
CTD |
PMID:22954530 |
|
NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases activity |
EXP |
Digoxin results in decreased activity of GSR protein |
CTD |
PMID:26820767 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases activity affects localization |
ISO |
2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate inhibits the reaction [Digoxin affects the localization of HIF1A protein]; 2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate inhibits the reaction [Digoxin results in increased phosphorylation of HIF1A protein]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole inhibits the reaction [Digoxin affects the localization of HIF1A protein]; Digoxin results in increased phosphorylation of and results in increased expression of HIF1A protein; KN 93 inhibits the reaction [Digoxin affects the localization of HIF1A protein]; KN 93 inhibits the reaction [Digoxin results in increased phosphorylation of HIF1A protein] Digoxin results in increased activity of HIF1A protein |
CTD |
PMID:19647009 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Digoxin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[Digoxin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il6r |
interleukin 6 receptor |
decreases expression |
ISO |
Digoxin results in decreased expression of IL6R protein modified form |
CTD |
PMID:20116850 |
|
NCBI chr 2:189,196,180...189,255,987
Ensembl chr 2:189,205,701...189,254,628
|
|
G |
Ins2 |
insulin 2 |
decreases response to substance |
ISO EXP |
INS protein results in decreased susceptibility to Digoxin |
CTD |
PMID:22562035 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions affects response to substance decreases expression decreases activity |
ISO |
Astemizole inhibits the reaction [Digoxin results in decreased activity of KCNH2 protein]; Astemizole inhibits the reaction [Digoxin results in decreased metabolism of KCNH2 protein modified form]; Sodium deficiency inhibits the reaction [Digoxin results in decreased expression of KCNH2 protein] KCNH2 gene affects the susceptibility to Digoxin Digoxin results in decreased expression of KCNH2 protein modified form |
CTD |
PMID:19139152 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
EXP |
N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine inhibits the reaction [Digoxin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:19687166 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
EXP |
Digoxin results in increased phosphorylation of MAPK3 protein N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine inhibits the reaction [Digoxin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:19687166 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Nos3 |
nitric oxide synthase 3 |
decreases response to substance |
ISO |
NOS3 protein results in decreased susceptibility to Digoxin |
CTD |
PMID:11761419 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions increases expression |
EXP |
N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine inhibits the reaction [Digoxin results in increased expression of NPPA mRNA] |
CTD |
PMID:19687166 |
|
NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
|
|
G |
Nppb |
natriuretic peptide B |
increases expression |
ISO |
Digoxin results in increased expression of NPPB protein |
CTD |
PMID:16032632 |
|
NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
Digoxin inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] |
CTD |
PMID:25257666 |
|
NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
decreases activity |
EXP |
Digoxin results in decreased activity of PGD protein |
CTD |
PMID:26820767 |
|
NCBI chr 5:165,966,128...165,982,327
|
|
G |
Rorc |
RAR-related orphan receptor C |
decreases activity |
ISO |
Digoxin results in decreased activity of RORC protein |
CTD |
PMID:21441909 |
|
NCBI chr 2:195,612,471...195,636,797
Ensembl chr 2:195,617,021...195,637,630
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
Digoxin inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:21641380 |
|
NCBI chr 1:48,273,639...48,300,645
Ensembl chr 1:48,273,611...48,300,655
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions |
ISO |
Digoxin inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:21641380 |
|
NCBI chr 1:48,433,079...48,521,261
Ensembl chr 1:48,433,079...48,521,256
|
|
G |
Slc9a1 |
solute carrier family 9 member A1 |
increases expression multiple interactions |
EXP |
Digoxin results in increased expression of SLC9A1 mRNA N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine inhibits the reaction [Digoxin results in increased expression of SLC9A1 mRNA] |
CTD |
PMID:19687166 |
|
NCBI chr 5:151,573,122...151,626,360
Ensembl chr 5:151,573,092...151,627,316
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
multiple interactions increases uptake decreases activity affects transport |
ISO EXP |
Elacridar affects the reaction [SLCO1A4 protein affects the transport of Digoxin] SLCO1A4 protein results in increased uptake of Digoxin Digoxin inhibits the reaction [SLCO1A4 protein results in increased uptake of Digoxin]; Quinine inhibits the reaction [SLCO1A4 protein results in increased uptake of Digoxin]; Rifampin inhibits the reaction [SLCO1A4 protein results in increased uptake of Digoxin] Digoxin results in decreased activity of SLCO1A4 protein |
CTD |
PMID:11883641 PMID:19833843 |
|
NCBI chr 4:175,969,549...176,026,227
Ensembl chr 4:175,969,549...176,026,163
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Digoxin results in decreased expression of VEGFA protein |
CTD |
PMID:20116850 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
EXP |
dioscin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 mRNA]; dioscin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 protein] |
CTD |
PMID:27317372 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases expression |
ISO EXP |
dioscin results in decreased expression of ABCB1 mRNA; dioscin results in decreased expression of ABCB1 protein |
CTD |
PMID:24680847 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
EXP |
dioscin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCC2 mRNA]; dioscin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCC2 protein] |
CTD |
PMID:27317372 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in decreased expression of ACADM protein] |
CTD |
PMID:24146112 |
|
NCBI chr 2:260,124,418...260,148,589
Ensembl chr 2:260,124,418...260,148,589
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in decreased expression of ACADS protein] |
CTD |
PMID:24146112 |
|
NCBI chr12:47,254,503...47,263,747
Ensembl chr12:47,254,484...47,263,747
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:24146112 |
|
NCBI chr10:104,724,534...104,748,003
Ensembl chr10:104,722,958...104,748,050
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in decreased expression of ACSL1 protein] |
CTD |
PMID:24146112 |
|
NCBI chr16:48,937,456...49,003,898
Ensembl chr16:48,937,456...49,003,246
|
|
G |
Acsl5 |
acyl-CoA synthetase long-chain family member 5 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in decreased expression of ACSL5 protein] |
CTD |
PMID:24146112 |
|
NCBI chr 1:276,240,703...276,290,012
Ensembl chr 1:276,240,703...276,290,008
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases expression |
ISO |
dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of AKT1 protein] dioscin results in decreased expression of AKT1 mRNA |
CTD |
PMID:25111127 PMID:29990575 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Aldh7a1 |
aldehyde dehydrogenase 7 family, member A1 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in decreased expression of ALDH7A1 protein] |
CTD |
PMID:24146112 |
|
NCBI chr18:51,619,007...51,651,267
Ensembl chr18:51,619,007...51,651,267
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased expression of ATF6 protein] |
CTD |
PMID:24146112 |
|
NCBI chr13:89,053,457...89,242,531
Ensembl chr13:89,055,983...89,242,443
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions increases expression |
ISO |
dioscin inhibits the reaction [Acetaminophen results in increased expression of BAK1 protein] dioscin results in increased expression of BAK1 mRNA; dioscin results in increased expression of BAK1 protein |
CTD |
PMID:22334414 PMID:22939915 PMID:29990575 |
|
NCBI chr20:5,609,620...5,618,899
Ensembl chr20:5,609,625...5,618,260
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
dioscin inhibits the reaction [Acetaminophen results in increased expression of BAX protein] dioscin results in increased expression of BAX protein |
CTD |
PMID:22334414 PMID:22939915 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
ISO |
dioscin results in increased expression of BBC3 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr 1:78,261,491...78,267,802
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression decreases expression |
ISO |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein] dioscin results in increased expression of BCL2 protein dioscin results in decreased expression of BCL2 mRNA; dioscin results in decreased expression of BCL2 protein |
CTD |
PMID:22334414 PMID:22939915 PMID:24742230 PMID:29990575 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
dioscin results in decreased expression of BCL2L1 mRNA; dioscin results in decreased expression of BCL2L1 protein |
CTD |
PMID:22334414 PMID:29990575 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions decreases expression |
ISO |
[Acetaminophen co-treated with dioscin] results in increased expression of BID protein dioscin results in decreased expression of BID mRNA; dioscin results in decreased expression of BID protein |
CTD |
PMID:22334414 PMID:22939915 |
|
NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression |
ISO |
dioscin results in increased expression of BIRC5 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression increases activity |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased expression of CASP3 protein] dioscin results in increased expression of CASP3 mRNA; dioscin results in increased expression of CASP3 protein benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [dioscin results in increased expression of CASP3 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [dioscin results in increased expression of CASP3 protein] dioscin results in increased activity of CASP3 protein |
CTD |
PMID:22334414 PMID:24146112 PMID:29990575 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
increases expression |
ISO |
dioscin results in increased expression of CASP7 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp8 |
caspase 8 |
increases activity increases expression |
ISO |
dioscin results in increased activity of CASP8 protein dioscin results in increased expression of CASP8 mRNA; dioscin results in increased expression of CASP8 protein |
CTD |
PMID:22334414 PMID:29990575 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases expression |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased expression of CASP9 protein] dioscin results in increased expression of CASP9 mRNA; dioscin results in increased expression of CASP9 protein |
CTD |
PMID:24146112 PMID:29990575 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
dioscin results in decreased expression of CCNB1 mRNA; dioscin results in decreased expression of CCNB1 protein |
CTD |
PMID:29990575 |
|
NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
ISO |
dioscin results in increased expression of CCND1 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
dioscin results in decreased expression of CDK1 mRNA; dioscin results in decreased expression of CDK1 protein |
CTD |
PMID:29990575 |
|
NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
dioscin results in increased expression of CDKN1A mRNA; dioscin results in increased expression of CDKN1A protein |
CTD |
PMID:29990575 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Chek2 |
checkpoint kinase 2 |
decreases expression |
ISO |
dioscin results in decreased expression of CHEK2 mRNA; dioscin results in decreased expression of CHEK2 protein |
CTD |
PMID:29990575 |
|
NCBI chr12:51,845,574...51,878,098
Ensembl chr12:51,845,796...51,877,624
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in decreased expression of CPT1A mRNA] |
CTD |
PMID:24146112 |
|
NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression multiple interactions |
ISO |
dioscin results in increased expression of CTNNB1 mRNA; dioscin results in increased expression of CTNNB1 protein fulvestrant inhibits the reaction [dioscin results in increased expression of CTNNB1 mRNA] |
CTD |
PMID:24742230 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
increases expression |
ISO |
dioscin results in increased expression of CYP2C9 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Acetaminophen results in increased expression of and results in increased activity of CYP2E1 protein]; dioscin inhibits the reaction [Ethanol results in increased expression of and results in increased activity of CYP2E1 protein] |
CTD |
PMID:22939915 PMID:24146112 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in increased expression of DGAT1 mRNA] |
CTD |
PMID:24146112 |
|
NCBI chr 7:117,566,363...117,576,735
Ensembl chr 7:117,566,368...117,576,737
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in increased expression of DGAT2 mRNA] |
CTD |
PMID:24146112 |
|
NCBI chr 1:164,113,459...164,143,818
Ensembl chr 1:164,113,459...164,143,818
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
increases expression |
ISO |
dioscin results in increased expression of DIABLO mRNA |
CTD |
PMID:29990575 |
|
NCBI chr12:38,490,230...38,503,344
Ensembl chr12:38,490,230...38,503,330
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression multiple interactions |
ISO |
dioscin results in increased expression of ESR1 protein fulvestrant inhibits the reaction [dioscin results in increased expression of ESR1 protein] |
CTD |
PMID:24742230 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [dioscin results in increased expression of ESR2 protein] |
CTD |
PMID:24742230 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
Fadd |
Fas associated via death domain |
increases expression |
ISO |
dioscin results in increased expression of FADD mRNA; dioscin results in increased expression of FADD protein |
CTD |
PMID:22334414 PMID:29990575 |
|
NCBI chr 1:217,746,176...217,748,581
Ensembl chr 1:217,742,929...217,748,628
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
dioscin results in increased expression of FAS mRNA; dioscin results in increased expression of FAS protein |
CTD |
PMID:22334414 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
dioscin results in increased expression of FASLG mRNA; dioscin results in increased expression of FASLG protein |
CTD |
PMID:22334414 PMID:29990575 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
dioscin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of GPT protein] |
CTD |
PMID:27317372 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in decreased expression of GSR protein] |
CTD |
PMID:24146112 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
EXP |
dioscin inhibits the reaction [Doxorubicin results in increased expression of HMGB1 protein] dioscin inhibited the reaction [thioacetamide increased expression of Hmgb1 protein in liver] |
CTD |
PMID:28082111, PMID:29091898 |
RGD:15090820 |
NCBI chr12:7,082,529...7,090,246
Ensembl chr16:37,500,017...37,502,237
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
dioscin inhibits the reaction [Doxorubicin results in decreased expression of HMOX1 protein] dioscin inhibited the reaction [thioacetamide decreased expression of Hmox1 protein in liver] |
CTD |
PMID:28082111, PMID:29091898 |
RGD:15090820 |
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased expression of HSPA5 protein] |
CTD |
PMID:24146112 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
dioscin inhibited the reaction [thioacetamide increased expression of Icam1 protein in liver] |
RGD |
PMID:29091898 |
RGD:15090820 |
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
dioscin inhibits the reaction [Doxorubicin results in increased expression of IL1B mRNA]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of IL1B mRNA]] dioscin inhibited the reaction [thioacetamide increased expression of IL-1b mRNA in liver] |
CTD |
PMID:28082111, PMID:29091898 |
RGD:15090820 |
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in increased expression of IL6 mRNA] dioscin inhibited the reaction [thioacetamide increased expression of IL-6 mRNA in liver] dioscin inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]; dioscin inhibits the reaction [Ethanol results in increased expression of IL6 mRNA]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]] |
CTD |
PMID:24146112 PMID:28082111, PMID:29091898 |
RGD:15090820 |
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Kdr |
kinase insert domain receptor |
multiple interactions |
ISO |
dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of KDR protein] |
CTD |
PMID:25111127 |
|
NCBI chr14:34,727,677...34,787,127
Ensembl chr14:34,727,623...34,787,183
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
EXP |
dioscin inhibits the reaction [Doxorubicin results in increased expression of KEAP1 protein] |
CTD |
PMID:28082111 |
|
NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
|
|
G |
Krt18 |
keratin 18 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Acetaminophen results in increased expression of KRT18 protein]; dioscin inhibits the reaction [Ethanol results in increased expression of KRT18 protein] |
CTD |
PMID:22939915 PMID:24146112 |
|
NCBI chr 7:143,629,455...143,633,131
Ensembl chr 7:143,629,455...143,633,131
|
|
G |
Lrp5 |
LDL receptor related protein 5 |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [dioscin results in increased expression of LRP5 mRNA]; LRP5 protein affects the reaction [dioscin results in increased expression of TNFRSF11B mRNA]; LRP5 protein affects the reaction [dioscin results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:24742230 |
|
NCBI chr 1:218,816,833...218,920,147
Ensembl chr 1:218,816,841...218,920,094
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased phosphorylation of MAPK1 protein] dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:24146112 PMID:25111127 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased phosphorylation of MAPK3 protein] dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:24146112 PMID:25111127 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases expression |
ISO |
dioscin results in increased expression of MAPK8 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases expression |
ISO |
dioscin results in increased expression of MAPK9 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
|
|
G |
Mdh1 |
malate dehydrogenase 1 |
multiple interactions |
ISO |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of MDH1 protein] |
CTD |
PMID:22939915 |
|
NCBI chr14:106,378,349...106,393,642
Ensembl chr14:106,378,942...106,393,670
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases expression |
ISO |
dioscin results in decreased expression of MTOR mRNA |
CTD |
PMID:29990575 |
|
NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions |
EXP |
dioscin inhibits the reaction [Doxorubicin results in decreased expression of and affects the localization of NFE2L2 protein]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein]] dioscin inhibited the reaction [thioacetamide decreased expression of Nfe2L2 protein in liver] |
CTD |
PMID:28082111, PMID:29091898 |
RGD:15090820 |
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
dioscin inhibited the reaction [thioacetamide increased expression of Nfkb1 protein in liver] |
RGD |
PMID:29091898 |
RGD:15090820 |
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases degradation |
ISO |
dioscin results in decreased degradation of NFKBIA protein |
CTD |
PMID:24680847 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
dioscin inhibited the reaction [thioacetamide decreased expression of Nqo1 protein in liver] |
RGD |
PMID:29091898 |
RGD:15090820 |
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions increases expression |
EXP |
dioscin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of NR0B2 mRNA] dioscin results in increased expression of NR0B2 mRNA |
CTD |
PMID:27317372 |
|
NCBI chr 5:151,776,004...151,779,319
Ensembl chr 5:151,776,004...151,779,319
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
EXP |
dioscin inhibits the reaction [Doxorubicin results in decreased expression of NR1H4 protein]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein]]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of IL1B mRNA]]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of RELA protein]]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]] dioscin inhibited the reaction [thioacetamide decreased expression of Nr1h4 protein in liver] |
CTD |
PMID:28082111, PMID:29091898 |
RGD:15090820 |
NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases expression |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in increased expression of PARP1 protein] dioscin results in increased expression of PARP1 mRNA |
CTD |
PMID:24146112 PMID:29990575 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pik3cb |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta |
decreases expression |
ISO |
dioscin results in decreased expression of PIK3CB mRNA |
CTD |
PMID:29990575 |
|
NCBI chr 8:107,275,849...107,381,088
Ensembl chr 8:107,275,725...107,380,933
|
|
G |
Pnp |
purine nucleoside phosphorylase |
multiple interactions |
ISO |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of PNP protein] |
CTD |
PMID:22939915 |
|
NCBI chr15:27,875,883...27,883,566
Ensembl chr15:27,875,911...27,883,350
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in decreased expression of PPARA protein] |
CTD |
PMID:24146112 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Prdx1 |
peroxiredoxin 1 |
multiple interactions |
ISO |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of PRDX1 protein] |
CTD |
PMID:22939915 |
|
NCBI chr 5:135,536,413...135,551,986
Ensembl chr 5:135,536,413...135,551,990
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
EXP |
dioscin inhibited the reaction [thioacetamide decreased expression of Prkaa1 protein in liver] |
RGD |
PMID:29091898 |
RGD:15090820 |
NCBI chr 2:54,857,688...54,893,404
Ensembl chr 2:54,857,688...54,893,404
|
|
G |
Prkab1 |
protein kinase AMP-activated non-catalytic subunit beta 1 |
increases expression |
ISO |
dioscin results in increased expression of PRKAB1 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr12:46,316,298...46,326,789
Ensembl chr12:46,316,236...46,326,790
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
dioscin inhibited the reaction [thioacetamide increased expression of Ptgs2 protein in liver] |
RGD |
PMID:29091898 |
RGD:15090820 |
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
multiple interactions |
ISO |
dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:25111127 |
|
NCBI chr 7:114,436,419...114,611,317
Ensembl chr 7:114,437,361...114,590,119
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
dioscin inhibits the reaction [Doxorubicin results in increased expression of RELA protein]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of RELA protein]] |
CTD |
PMID:28082111 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Rgn |
regucalcin |
multiple interactions |
ISO |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of RGN protein] |
CTD |
PMID:22939915 |
|
NCBI chr X:1,833,484...1,848,904
Ensembl chr X:1,833,492...1,848,904
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases expression |
ISO |
dioscin results in decreased expression of RPS6KB1 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
multiple interactions |
EXP |
dioscin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA] |
CTD |
PMID:27317372 |
|
NCBI chr 6:104,617,730...104,631,355
Ensembl chr 6:104,617,730...104,631,355
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
increases expression |
EXP |
dioscin results in increased expression of SLCO1A2 mRNA |
CTD |
PMID:27317372 |
|
NCBI chr 4:175,969,549...176,026,227
Ensembl chr 4:175,969,549...176,026,163
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions increases expression |
EXP |
dioscin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLCO1B2 mRNA]; dioscin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLCO1B2 protein] dioscin results in increased expression of SLCO1B2 mRNA |
CTD |
PMID:27317372 |
|
NCBI chr 4:175,814,118...175,881,775
Ensembl chr 4:175,814,118...175,881,768
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of SRC protein] |
CTD |
PMID:25111127 |
|
NCBI chr 3:153,547,807...153,595,643
Ensembl chr 3:153,580,861...153,595,642
|
|
G |
Suox |
sulfite oxidase |
multiple interactions |
ISO |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of SUOX protein] |
CTD |
PMID:22939915 |
|
NCBI chr 7:3,098,228...3,102,179
Ensembl chr 7:3,098,245...3,102,142
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in increased expression of TNF mRNA] dioscin inhibited the reaction [thioacetamide increased expression of Tnfa mRNA in liver] dioscin results in increased expression of TNF mRNA; dioscin results in increased expression of TNF protein dioscin inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]; dioscin inhibits the reaction [Ethanol results in increased expression of TNF mRNA]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]] |
CTD |
PMID:22334414 PMID:24146112 PMID:28082111 PMID:29990575, PMID:29091898 |
RGD:15090820 |
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
increases expression multiple interactions |
ISO |
dioscin results in increased expression of TNFRSF11B mRNA fulvestrant inhibits the reaction [dioscin results in increased expression of TNFRSF11B mRNA]; LRP5 protein affects the reaction [dioscin results in increased expression of TNFRSF11B mRNA] |
CTD |
PMID:24742230 |
|
NCBI chr 7:93,798,580...93,826,586
Ensembl chr 7:93,798,545...93,826,665
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases expression |
ISO |
dioscin results in increased expression of TNFRSF1A mRNA; dioscin results in increased expression of TNFRSF1A protein |
CTD |
PMID:22334414 PMID:29990575 |
|
NCBI chr 4:157,864,905...157,877,634
Ensembl chr 4:157,864,969...157,877,633
|
|
G |
Tnfrsf25 |
TNF receptor superfamily member 25 |
increases expression |
ISO |
dioscin results in increased expression of TNFRSF25 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr 5:169,288,419...169,293,137
Ensembl chr 5:169,288,871...169,293,137
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
decreases expression multiple interactions |
ISO |
dioscin results in decreased expression of TNFSF11 mRNA fulvestrant inhibits the reaction [dioscin results in increased expression of TNFSF11 mRNA]; LRP5 protein affects the reaction [dioscin results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:24742230 |
|
NCBI chr15:60,482,527...60,512,704
Ensembl chr15:60,482,527...60,512,704
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO EXP |
dioscin inhibits the reaction [Acetaminophen results in increased expression of TRP53 protein]; dioscin inhibits the reaction [Ethanol results in increased expression of TRP53 protein] dioscin results in increased expression of TP53 mRNA; dioscin results in increased expression of TP53 protein |
CTD |
PMID:22334414 PMID:22939915 PMID:24146112 PMID:29990575 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Tradd |
TNFRSF1A-associated via death domain |
increases expression |
ISO |
dioscin results in increased expression of TRADD mRNA |
CTD |
PMID:29990575 |
|
NCBI chr19:37,214,461...37,221,099
Ensembl chr19:37,214,471...37,216,572
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
increases expression |
ISO |
dioscin results in increased expression of TRAF1 protein |
CTD |
PMID:22334414 |
|
NCBI chr 3:14,003,340...14,022,955
Ensembl chr 3:14,003,340...14,022,672
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of AKT1 protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of KDR protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK1 protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK3 protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of PTK2 protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of SRC protein] |
CTD |
PMID:25111127 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Wee1 |
WEE1 G2 checkpoint kinase |
increases expression |
ISO |
dioscin results in increased expression of WEE1 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr 1:174,765,228...174,790,882
Ensembl chr 1:174,767,960...174,786,361
|
|
|
G |
Cxcr1 |
C-X-C motif chemokine receptor 1 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of CXCR1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 9:81,466,430...81,469,299
Ensembl chr 9:81,466,332...81,469,274
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Ifng |
interferon gamma |
decreases expression |
ISO |
ginsenoside M1 results in decreased expression of IFNG mRNA |
CTD |
PMID:15914323 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
ISO |
ginsenoside M1 results in decreased expression of IL1B mRNA |
CTD |
PMID:15914323 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il4 |
interleukin 4 |
decreases expression |
ISO |
ginsenoside M1 results in decreased expression of IL4 mRNA |
CTD |
PMID:15914323 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Itga4 |
integrin subunit alpha 4 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 3:66,178,745...66,265,547
Ensembl chr 3:66,193,059...66,263,960
|
|
G |
Itgal |
integrin subunit alpha L |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 1:198,744,053...198,781,745
Ensembl chr 1:198,744,050...198,781,750
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
|
|
G |
Itgb2 |
integrin subunit beta 2 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr20:11,777,773...11,815,647
Ensembl chr20:11,777,783...11,815,647
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases secretion |
ISO |
ginsenoside M1 results in decreased secretion of MMP9 protein |
CTD |
PMID:21875580 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
ginsenoside M1 results in decreased activity of [NFKB1 protein binds to RELA protein] |
CTD |
PMID:15802804 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
ginsenoside M1 results in decreased expression of and results in decreased activity of NOS2 protein |
CTD |
PMID:15802804 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
P2rx4 |
purinergic receptor P2X 4 |
multiple interactions |
ISO |
[ginsenoside M1 co-treated with Adenosine Triphosphate] results in increased activity of P2RX4 protein; ginsenoside M1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] |
CTD |
PMID:30545933 |
|
NCBI chr12:39,308,022...39,325,673
Ensembl chr12:39,308,025...39,325,673
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
decreases response to substance |
ISO |
P2RX7 gene mutant form results in decreased susceptibility to ginsenoside M1 |
CTD |
PMID:30545933 |
|
NCBI chr12:39,353,613...39,396,042
Ensembl chr12:39,353,613...39,396,042
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO EXP |
ginsenoside M1 results in decreased expression of PTGS2 mRNA ginsenoside M1 results in decreased expression of PTGS2 protein |
CTD |
PMID:15802804 PMID:15914323 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
ginsenoside M1 results in decreased activity of [NFKB1 protein binds to RELA protein] |
CTD |
PMID:15802804 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:21875580 |
|
NCBI chr13:82,355,234...82,365,323
Ensembl chr13:82,355,471...82,365,341
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression decreases response to substance |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of CXCR1 protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of SELE protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein] ginsenoside M1 results in decreased expression of TNF mRNA ginsenoside M1 results in decreased susceptibility to TNF protein |
CTD |
PMID:15914323 PMID:21875580 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
|
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside F1 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
ginsenoside F1 inhibits the reaction [Galactose affects the localization of RELA protein] |
CTD |
PMID:29412148 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
ginsenoside F2 analog inhibits the reaction [ABCB1 protein results in increased transport of Digoxin] |
CTD |
PMID:24380838 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:19781563 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions increases expression |
EXP |
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of BMP2 mRNA] ginsenoside Rb1 results in increased expression of BMP2 mRNA |
CTD |
PMID:27470910 |
|
NCBI chr 3:126,335,963...126,346,771
Ensembl chr 3:126,335,863...126,346,318
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein] |
CTD |
PMID:19781563 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA] |
CTD |
PMID:22386813 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; ginsenoside Rb1 results in increased expression of and results in increased activity of HMOX1 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein] [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein |
CTD |
PMID:19781563 PMID:25422538 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions increases expression |
EXP |
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of IGF1 mRNA] ginsenoside Rb1 results in increased expression of IGF1 mRNA |
CTD |
PMID:27470910 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
ginsenoside Rb1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:17655881 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
EXP |
ginsenoside Rb1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGAM protein] |
CTD |
PMID:17655881 |
|
NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
|
|
G |
Itgb2 |
integrin subunit beta 2 |
multiple interactions |
EXP |
ginsenoside Rb1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGB2 protein] |
CTD |
PMID:17655881 |
|
NCBI chr20:11,777,773...11,815,647
Ensembl chr20:11,777,783...11,815,647
|
|
G |
Kcne1 |
potassium voltage-gated channel subfamily E regulatory subunit 1 |
increases expression |
ISO |
ginsenoside Rb1 results in increased expression of KCNE1 |
CTD |
PMID:24615935 |
|
NCBI chr11:32,498,260...32,511,202
Ensembl chr11:32,498,261...32,508,420
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
affects activity |
ISO |
ginsenoside Rb1 affects the activity of KCNH2 protein |
CTD |
PMID:15842772 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
ISO |
ginsenoside Rb1 results in increased expression of MAP2 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 9:73,204,753...73,462,965
Ensembl chr 9:73,319,710...73,462,972
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA] |
CTD |
PMID:22386813 |
|
NCBI chr18:77,203,517...77,322,690
Ensembl chr18:77,203,525...77,322,690
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions affects localization increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; [ginsenoside Rb1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; ginsenoside Rb1 results in increased activity of and results in increased localization of NFE2L2 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein] ginsenoside Rb1 affects the localization of NFE2L2 protein [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein ginsenoside Rb1 results in increased expression of NFE2L2 mRNA |
CTD |
PMID:19781563 PMID:22780686 PMID:25422538 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
P2rx4 |
purinergic receptor P2X 4 |
multiple interactions |
ISO |
ginsenoside Rb1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] |
CTD |
PMID:30545933 |
|
NCBI chr12:39,308,022...39,325,673
Ensembl chr12:39,308,025...39,325,673
|
|
G |
Pgr |
progesterone receptor |
increases expression |
ISO |
ginsenoside Rb1 results in increased expression of PGR protein |
CTD |
PMID:16204943 |
|
NCBI chr 8:7,128,656...7,187,796
Ensembl chr 8:7,128,656...7,187,796
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein affects the localization of RELA protein] |
CTD |
PMID:22386813 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression multiple interactions |
EXP |
ginsenoside Rb1 results in increased expression of RUNX2 mRNA ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of RUNX2 mRNA] |
CTD |
PMID:27470910 |
|
NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
ginsenoside Rb1 binds to and results in decreased activity of SLCO1B3 protein |
CTD |
PMID:25297453 |
|
NCBI chr 4:175,814,118...175,881,775
Ensembl chr 4:175,814,118...175,881,768
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression |
EXP |
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of TGFB1 mRNA] ginsenoside Rb1 results in increased expression of TGFB1 mRNA |
CTD |
PMID:27470910 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of TNF mRNA] |
CTD |
PMID:22386813 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions decreases response to substance |
ISO |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein affects the localization of RELA protein]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of TNF mRNA] ginsenoside Rb1 results in decreased susceptibility to TNFSF11 protein |
CTD |
PMID:22386813 |
|
NCBI chr15:60,482,527...60,512,704
Ensembl chr15:60,482,527...60,512,704
|
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
EXP |
ginsenoside Rb2 results in increased expression of ABCC2 mRNA |
CTD |
PMID:23835644 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Lpl |
lipoprotein lipase |
increases secretion decreases secretion |
ISO |
ginsenoside Rb2 results in increased secretion of LPL protein ginsenoside Rb2 results in decreased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
ginsenoside Rc binds to and results in decreased activity of SLCO1B3 protein |
CTD |
PMID:25297453 |
|
NCBI chr 4:175,814,118...175,881,775
Ensembl chr 4:175,814,118...175,881,768
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
ginsenoside Rd results in increased phosphorylation of and results in increased activity of AKT1 protein |
CTD |
PMID:24599032 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
ginsenoside Rd inhibits the reaction [APP protein modified form results in decreased expression of BCL2 mRNA]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of BAX mRNA]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CASP3 protein modified form]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CYCS mRNA] |
CTD |
PMID:26111763 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of BAX mRNA] |
CTD |
PMID:26111763 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
ginsenoside Rd inhibits the reaction [APP protein modified form results in decreased expression of BCL2 mRNA] |
CTD |
PMID:26111763 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CASP3 protein modified form] |
CTD |
PMID:26111763 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cat |
catalase |
increases expression |
EXP |
ginsenoside Rd results in increased expression of CAT protein |
CTD |
PMID:9933756 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
ginsenoside Rd results in increased expression of CDKN1A mRNA staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CDKN1A mRNA] |
CTD |
PMID:24599032 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Chat |
choline O-acetyltransferase |
increases expression multiple interactions |
ISO |
ginsenoside Rd results in increased expression of CHAT mRNA; ginsenoside Rd results in increased expression of CHAT protein staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CHAT mRNA]; staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CHAT protein] |
CTD |
PMID:24599032 |
|
NCBI chr16:8,576,858...8,686,131
Ensembl chr16:8,577,840...8,686,131
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CYCS mRNA] |
CTD |
PMID:26111763 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Lpl |
lipoprotein lipase |
decreases secretion |
ISO |
ginsenoside Rd results in decreased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
ISO |
ginsenoside Rd results in increased expression of MAP2 mRNA; ginsenoside Rd results in increased expression of MAP2 protein |
CTD |
PMID:24599032 |
|
NCBI chr 9:73,204,753...73,462,965
Ensembl chr 9:73,319,710...73,462,972
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
ginsenoside Rd results in increased phosphorylation of and results in increased activity of MAPK1 protein |
CTD |
PMID:24599032 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
ginsenoside Rd results in increased phosphorylation of and results in increased activity of MAPK3 protein |
CTD |
PMID:24599032 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Ngf |
nerve growth factor |
increases expression |
ISO |
ginsenoside Rd results in increased expression of NGF mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
|
|
G |
Ngfr |
nerve growth factor receptor |
increases expression |
ISO |
ginsenoside Rd results in increased expression of NGFR mRNA; ginsenoside Rd results in increased expression of NGFR protein |
CTD |
PMID:24599032 |
|
NCBI chr10:83,389,828...83,408,061
Ensembl chr10:83,389,847...83,408,061
|
|
G |
P2rx4 |
purinergic receptor P2X 4 |
multiple interactions |
ISO |
ginsenoside Rd promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] |
CTD |
PMID:30545933 |
|
NCBI chr12:39,308,022...39,325,673
Ensembl chr12:39,308,025...39,325,673
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
decreases response to substance |
ISO |
P2RX7 gene mutant form results in decreased susceptibility to ginsenoside Rd |
CTD |
PMID:30545933 |
|
NCBI chr12:39,353,613...39,396,042
Ensembl chr12:39,353,613...39,396,042
|
|
G |
Slc18a3 |
solute carrier family 18 member A3 |
increases expression |
ISO |
ginsenoside Rd results in increased expression of SLC18A3 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr16:8,682,668...8,685,529
Ensembl chr16:8,682,669...8,685,529
|
|
G |
Slc5a7 |
solute carrier family 5 member 7 |
increases expression |
ISO |
ginsenoside Rd results in increased expression of SLC5A7 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 9:5,294,377...5,330,822
Ensembl chr 9:5,294,381...5,330,815
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
ginsenoside Rd binds to and results in decreased activity of SLCO1B3 protein |
CTD |
PMID:25297453 |
|
NCBI chr 4:175,814,118...175,881,775
Ensembl chr 4:175,814,118...175,881,768
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
increases transport |
EXP ISO |
ABCB11 protein results in increased transport of ginsenoside Re |
CTD |
PMID:25297453 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases transport |
ISO |
ABCC1 protein results in increased transport of ginsenoside Re |
CTD |
PMID:25297453 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases transport |
EXP ISO |
ABCC2 protein results in increased transport of ginsenoside Re |
CTD |
PMID:25297453 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases transport |
EXP ISO |
ABCG2 protein results in increased transport of ginsenoside Re |
CTD |
PMID:25297453 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression multiple interactions |
ISO |
ginsenoside Re results in increased expression of ADIPOQ mRNA ginsenoside Re results in increased expression of and results in increased secretion of ADIPOQ protein |
CTD |
PMID:23545455 |
|
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
multiple interactions |
ISO |
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of AIF1 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]] |
CTD |
PMID:29467000 |
|
NCBI chr20:5,161,350...5,167,176
Ensembl chr20:5,161,333...5,166,448
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
ginsenoside Re results in increased phosphorylation of and results in increased activity of AKT1 protein ginsenoside Re results in increased phosphorylation of AKT1 protein |
CTD |
PMID:17878692 PMID:17885204 PMID:24599032 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
ginsenoside Re binds to and affects the activity of AR protein |
CTD |
PMID:16985185 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
ginsenoside Re results in decreased expression of BAX mRNA; ginsenoside Re results in decreased expression of BAX protein 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of BAX protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]] |
CTD |
PMID:12674765 PMID:15621629 PMID:29467000 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression multiple interactions |
ISO |
ginsenoside Re results in increased expression of BCL2 mRNA; ginsenoside Re results in increased expression of BCL2 protein 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of BCL2 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]] |
CTD |
PMID:15621629 PMID:29467000 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]; ginsenoside Re results in decreased cleavage of and results in decreased activity of CASP3 protein; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]] |
CTD |
PMID:15621629 PMID:23102375 PMID:25523949 PMID:29467000 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]] |
CTD |
PMID:24430743 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
ginsenoside Re results in increased expression of CDKN1A mRNA |
CTD |
PMID:24599032 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Chat |
choline O-acetyltransferase |
increases expression multiple interactions |
ISO |
ginsenoside Re results in increased expression of CHAT mRNA; ginsenoside Re results in increased expression of CHAT protein staurosporine aglycone inhibits the reaction [ginsenoside Re results in increased expression of CHAT mRNA]; staurosporine aglycone inhibits the reaction [ginsenoside Re results in increased expression of CHAT protein] |
CTD |
PMID:24599032 |
|
NCBI chr16:8,576,858...8,686,131
Ensembl chr16:8,577,840...8,686,131
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of CHUK protein] |
CTD |
PMID:17885204 |
|
NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of CLDN1 protein] |
CTD |
PMID:22849695 |
|
NCBI chr11:77,815,216...77,830,373
Ensembl chr11:77,815,181...77,830,416
|
|
G |
Crp |
C-reactive protein |
increases expression |
EXP |
ginsenoside Re results in increased expression of CRP protein |
CTD |
PMID:16797897 |
|
NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of CYBA protein]]; ginsenoside Re inhibits the reaction [Phencyclidine results in increased activity of CYBA protein] |
CTD |
PMID:29037473 |
|
NCBI chr19:55,249,634...55,257,824
Ensembl chr19:55,249,616...55,257,876
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression |
EXP |
ginsenoside Re results in increased expression of CYP8B1 mRNA |
CTD |
PMID:23835644 |
|
NCBI chr 8:130,548,418...130,550,388
Ensembl chr 8:130,548,418...130,550,388
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
ginsenoside Re binds to and affects the activity of ESR1 protein |
CTD |
PMID:16985185 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression |
ISO |
ginsenoside Re results in increased expression of FABP4 mRNA |
CTD |
PMID:23545455 |
|
NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression multiple interactions |
ISO |
ginsenoside Re results in decreased expression of FAS mRNA ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of FAS mRNA] |
CTD |
PMID:21971952 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
ginsenoside Re results in increased expression of FOS mRNA |
CTD |
PMID:16204943 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
ISO |
ginsenoside Re results in decreased expression of G6PC1 mRNA |
CTD |
PMID:21971952 |
|
NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
|
|
G |
Gpam |
glycerol-3-phosphate acyltransferase, mitochondrial |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of GPAM mRNA] |
CTD |
PMID:21971952 |
|
NCBI chr 1:275,843,823...275,906,880
Ensembl chr 1:275,846,819...275,906,686
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine affects the localization of NCF1 protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in decreased activity of SOD2 protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of CYBA protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of SOD1 protein]] |
CTD |
PMID:29037473 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation |
ISO |
ginsenoside Re results in increased phosphorylation of GSK3B protein |
CTD |
PMID:17885204 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
increases expression |
ISO |
ginsenoside Re results in increased expression of HSPD1 protein |
CTD |
PMID:23144451 |
|
NCBI chr 9:61,680,529...61,691,202
Ensembl chr 9:61,680,530...61,690,956
|
|
G |
Ifng |
interferon gamma |
decreases expression |
ISO |
ginsenoside Re results in decreased expression of IFNG protein |
CTD |
PMID:20230918 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of IKBKB protein] |
CTD |
PMID:22849695 |
|
NCBI chr16:74,177,233...74,230,809
Ensembl chr16:74,177,215...74,230,815
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of IL1B mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL1B mRNA] |
CTD |
PMID:16557482 PMID:22494059 PMID:22849695 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [TNF protein results in increased expression of IL6 mRNA] |
CTD |
PMID:17885204 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased degradation of IRAK1 protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of IRAK1 protein] |
CTD |
PMID:22849695 |
|
NCBI chr X:156,716,469...156,726,367
Ensembl chr X:156,716,604...156,725,977
|
|
G |
Irak4 |
interleukin-1 receptor-associated kinase 4 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased degradation of IRAK4 protein] |
CTD |
PMID:22849695 |
|
NCBI chr 7:135,803,723...135,831,006
Ensembl chr 7:135,803,698...135,832,652
|
|
G |
Irgm |
immunity-related GTPase M |
decreases expression |
ISO |
ginsenoside Re results in decreased expression of IRGM protein |
CTD |
PMID:20230918 |
|
NCBI chr10:34,213,885...34,221,968
Ensembl chr10:34,213,936...34,221,928
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions increases expression increases phosphorylation |
ISO |
ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of IRS1 protein] ginsenoside Re results in increased expression of IRS1 mRNA ginsenoside Re results in increased phosphorylation of IRS1 protein |
CTD |
PMID:17885204 PMID:23545455 |
|
NCBI chr 9:88,033,668...88,086,488
Ensembl chr 9:88,033,668...88,086,488
|
|
G |
Kcne1 |
potassium voltage-gated channel subfamily E regulatory subunit 1 |
increases expression |
ISO |
ginsenoside Re results in increased expression of KCNE1 |
CTD |
PMID:24615935 |
|
NCBI chr11:32,498,260...32,511,202
Ensembl chr11:32,498,261...32,508,420
|
|
G |
Lpl |
lipoprotein lipase |
increases secretion |
ISO |
ginsenoside Re results in increased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Lrpprc |
leucine-rich pentatricopeptide repeat containing |
increases expression |
ISO |
ginsenoside Re results in increased expression of LRPPRC protein |
CTD |
PMID:23144451 |
|
NCBI chr 6:7,984,043...8,066,874
Ensembl chr 6:7,984,019...8,066,868
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
ISO |
ginsenoside Re results in increased expression of MAP2 mRNA; ginsenoside Re results in increased expression of MAP2 protein |
CTD |
PMID:24599032 |
|
NCBI chr 9:73,204,753...73,462,965
Ensembl chr 9:73,319,710...73,462,972
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
ginsenoside Re results in increased phosphorylation of and results in increased activity of MAPK1 protein |
CTD |
PMID:24599032 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
ginsenoside Re results in increased phosphorylation of and results in increased activity of MAPK3 protein |
CTD |
PMID:24599032 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:22849695 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Myl9 |
myosin light chain 9 |
affects phosphorylation |
EXP |
ginsenoside Re affects the phosphorylation of MYL9 protein |
CTD |
PMID:24658813 |
|
NCBI chr 3:152,857,573...152,863,961
Ensembl chr 3:152,857,592...152,863,960
|
|
G |
Mylk |
myosin light chain kinase |
affects expression |
EXP |
ginsenoside Re affects the expression of MYLK mRNA; ginsenoside Re affects the expression of MYLK protein |
CTD |
PMID:24658813 |
|
NCBI chr11:69,013,060...69,260,039
Ensembl chr11:69,013,050...69,223,158
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine affects the localization of NCF1 protein]]; ginsenoside Re inhibits the reaction [Phencyclidine affects the localization of NCF1 protein] |
CTD |
PMID:29037473 |
|
NCBI chr12:25,497,104...25,506,300
Ensembl chr12:25,497,104...25,506,300
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO EXP |
ginsenoside Re inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein] |
CTD |
PMID:17885204 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Ngf |
nerve growth factor |
increases expression |
ISO |
ginsenoside Re results in increased expression of NGF mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
|
|
G |
Ngfr |
nerve growth factor receptor |
increases expression |
ISO |
ginsenoside Re results in increased expression of NGFR mRNA; ginsenoside Re results in increased expression of NGFR protein |
CTD |
PMID:24599032 |
|
NCBI chr10:83,389,828...83,408,061
Ensembl chr10:83,389,847...83,408,061
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression |
ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] ginsenoside Re results in decreased expression of NOS2 protein |
CTD |
PMID:15621629 PMID:23102375 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions increases phosphorylation |
ISO |
2-aminoethoxydiphenyl borate inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein]; Calcium deficiency inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein]; Mifepristone inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein] |
CTD |
PMID:17490654 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression |
ISO |
ginsenoside Re results in increased expression of NR0B2 mRNA |
CTD |
PMID:21971952 |
|
NCBI chr 5:151,776,004...151,779,319
Ensembl chr 5:151,776,004...151,779,319
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions increases activity |
ISO |
[ginsenoside Re results in increased activity of NR3C1 protein] which results in increased abundance of Nitric Oxide |
CTD |
PMID:17490654 |
|
NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
|
|
G |
Ocln |
occludin |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of OCLN protein] |
CTD |
PMID:22849695 |
|
NCBI chr 2:30,527,327...30,577,218
Ensembl chr 2:30,527,715...30,577,218
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Methamphetamine results in increased cleavage of PARP1 protein] |
CTD |
PMID:25523949 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions decreases expression |
ISO |
ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of PCK1 mRNA] ginsenoside Re results in decreased expression of PCK1 mRNA |
CTD |
PMID:21971952 |
|
NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
|
|
G |
Pdyn |
prodynorphin |
multiple interactions |
ISO |
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of PDYN mRNA]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]] |
CTD |
PMID:29467000 |
|
NCBI chr 3:122,194,327...122,206,671
Ensembl chr 3:122,194,329...122,206,671
|
|
G |
Pgr |
progesterone receptor |
multiple interactions increases expression |
ISO |
ginsenoside Re binds to and affects the activity of PGR protein ginsenoside Re results in increased expression of PGR protein |
CTD |
PMID:16204943 PMID:16985185 |
|
NCBI chr 8:7,128,656...7,187,796
Ensembl chr 8:7,128,656...7,187,796
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
ginsenoside Re results in increased expression of PPARG mRNA |
CTD |
PMID:23545455 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases phosphorylation multiple interactions |
ISO |
ginsenoside Re results in increased phosphorylation of PRKAA1 protein ginsenoside Re inhibits the reaction [Dietary Fats results in decreased phosphorylation of PRKAA1 protein] |
CTD |
PMID:21971952 |
|
NCBI chr 2:54,857,688...54,893,404
Ensembl chr 2:54,857,688...54,893,404
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions increases response to substance |
ISO |
ginsenoside Re inhibits the reaction [Methamphetamine affects the localization of PRKCD protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]] ginsenoside Re inhibits the reaction [Methamphetamine affects the localization of PRKCD protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of and results in increased cleavage of PRKCD protein] PRKCD results in increased susceptibility to ginsenoside Re |
CTD |
PMID:24430743 PMID:25523949 |
|
NCBI chr16:6,655,131...6,675,746
Ensembl chr16:6,655,120...6,675,746
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of PTGS2 mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA] |
CTD |
PMID:16557482 PMID:23102375 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
increases phosphorylation |
ISO |
ginsenoside Re results in increased phosphorylation of RPS6KB1 protein |
CTD |
PMID:17885204 |
|
NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression multiple interactions |
ISO |
ginsenoside Re results in decreased expression of SCD mRNA ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of SCD1 mRNA] |
CTD |
PMID:21971952 |
|
NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
|
|
G |
Slc18a3 |
solute carrier family 18 member A3 |
increases expression |
ISO |
ginsenoside Re results in increased expression of SLC18A3 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr16:8,682,668...8,685,529
Ensembl chr16:8,682,669...8,685,529
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions increases localization |
EXP ISO |
ginsenoside Re inhibits the reaction [Dietary Fats inhibits the reaction [INS1 protein results in increased localization of SLC2A4 protein]] ginsenoside Re results in increased localization of SLC2A4 protein |
CTD |
PMID:17885204 PMID:22571876 PMID:23545455 |
|
NCBI chr10:56,552,921...56,558,562
Ensembl chr10:56,552,983...56,558,487
|
|
G |
Slc5a7 |
solute carrier family 5 member 7 |
increases expression |
ISO |
ginsenoside Re results in increased expression of SLC5A7 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 9:5,294,377...5,330,822
Ensembl chr 9:5,294,381...5,330,815
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
EXP ISO |
SLCO1B2 protein binds to and results in increased transport of ginsenoside Re SLCO1B3 protein binds to and results in increased transport of ginsenoside Re |
CTD |
PMID:25297453 |
|
NCBI chr 4:175,814,118...175,881,775
Ensembl chr 4:175,814,118...175,881,768
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [TNF protein results in increased expression of SOCS3 mRNA] |
CTD |
PMID:17885204 |
|
NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of SOD1 protein]]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]] |
CTD |
PMID:24430743 PMID:29037473 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in decreased activity of SOD2 protein]] |
CTD |
PMID:29037473 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions decreases expression |
ISO |
ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA] ginsenoside Re results in decreased expression of SREBF1 mRNA |
CTD |
PMID:21971952 |
|
NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
|
|
G |
Stk11 |
serine/threonine kinase 11 |
increases phosphorylation |
ISO |
ginsenoside Re results in increased phosphorylation of STK11 protein |
CTD |
PMID:21971952 |
|
NCBI chr 7:12,440,751...12,457,513
Ensembl chr 7:12,440,751...12,457,513
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 mRNA]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 protein modified form]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 mRNA]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 protein modified form]] |
CTD |
PMID:29467000 |
|
NCBI chr 4:33,638,853...33,646,819
Ensembl chr 4:33,638,709...33,646,819
|
|
G |
Tbc1d4 |
TBC1 domain family, member 4 |
increases phosphorylation |
ISO |
ginsenoside Re results in increased phosphorylation of TBC1D4 protein |
CTD |
PMID:17885204 |
|
NCBI chr15:85,927,978...86,105,829
Ensembl chr15:85,930,044...86,105,273
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
ginsenoside Re results in increased expression of TFF1 mRNA |
CTD |
PMID:16204943 |
|
NCBI chr20:9,892,124...9,895,984
Ensembl chr20:9,892,124...9,895,984
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of and results in decreased activity of TH protein] 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of TH protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]] |
CTD |
PMID:25523949 PMID:29467000 |
|
NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of TJP1 protein] |
CTD |
PMID:22849695 |
|
NCBI chr 1:126,146,489...126,515,359
Ensembl chr 1:126,146,489...126,227,469
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides binds to TLR4 protein] |
CTD |
PMID:22849695 |
|
NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; ginsenoside Re inhibits the reaction [TNF protein results in increased expression of SOCS3 mRNA]; ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of CHUK protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of IRS1 protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of TNF mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF mRNA]; ginsenoside Re results in decreased expression of and results in decreased secretion of TNF protein |
CTD |
PMID:16557482 PMID:17885204 PMID:22494059 PMID:22849695 PMID:23545455 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions decreases expression |
ISO |
ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]; ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 protein]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]] ginsenoside Rf results in decreased expression of APOA1 protein |
CTD |
PMID:16297877 |
|
NCBI chr 8:50,525,091...50,526,875
Ensembl chr 8:50,525,091...50,526,875
|
|
G |
Apoc3 |
apolipoprotein C3 |
multiple interactions decreases expression increases expression |
ISO |
ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]; ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 protein]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf results in increased expression of APOC3 mRNA] ginsenoside Rf results in decreased expression of APOC3 protein |
CTD |
PMID:16297877 |
|
NCBI chr 8:50,529,318...50,531,498
Ensembl chr 8:50,529,318...50,531,498
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
affects activity |
ISO |
ginsenoside Rf affects the activity of KCNH2 protein |
CTD |
PMID:15842772 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions decreases expression |
ISO |
ginsenoside Rf binds to and results in decreased activity of PPARA protein; ginsenoside Rf inhibits the reaction [pirinixic acid results in increased activity of PPARA protein]; ginsenoside Rf inhibits the reaction [pirinixic acid results in increased expression of PPARA mRNA]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf results in increased expression of APOC3 mRNA] ginsenoside Rf results in decreased expression of PPARA mRNA |
CTD |
PMID:16297877 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
increases transport multiple interactions |
EXP ISO |
ABCB11 protein results in increased transport of ginsenoside Rg1 ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 protein] ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCB11 protein] |
CTD |
PMID:25297453 PMID:29964319 PMID:32198087 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases transport |
ISO |
ABCC1 protein results in increased transport of ginsenoside Rg1 |
CTD |
PMID:25297453 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases transport multiple interactions increases expression |
EXP ISO |
ABCC2 protein results in increased transport of ginsenoside Rg1 ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC2 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC2 protein] ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC2 protein]; Tretinoin inhibits the reaction [ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC2 protein]] ginsenoside Rg1 results in increased expression of ABCC2 protein |
CTD |
PMID:25297453 PMID:29964319 PMID:32198087 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression multiple interactions |
ISO |
ginsenoside Rg1 results in increased expression of ABCC3 protein ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC3 protein]; Tretinoin inhibits the reaction [ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC3 protein]] |
CTD |
PMID:29964319 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases expression multiple interactions |
ISO |
ginsenoside Rg1 results in increased expression of ABCC4 protein ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC4 protein] |
CTD |
PMID:29964319 |
|
NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases transport |
EXP ISO |
ABCG2 protein results in increased transport of ginsenoside Rg1 |
CTD |
PMID:25297453 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
ginsenoside Rg1 results in decreased activity of ACHE protein |
CTD |
PMID:20564503 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Adam10 |
ADAM metallopeptidase domain 10 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in decreased expression of ADAM10 mRNA] |
CTD |
PMID:22484447 |
|
NCBI chr 8:77,107,355...77,237,483
Ensembl chr 8:77,107,536...77,237,483
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in decreased expression of ADAM10 mRNA]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP mRNA]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein alternative form]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of BACE1 mRNA]; ginsenoside Rg1 results in decreased susceptibility to [APP protein alternative form co-treated with Dexamethasone] |
CTD |
PMID:22484447 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of ATF6 protein] |
CTD |
PMID:30918470 |
|
NCBI chr13:89,053,457...89,242,531
Ensembl chr13:89,055,983...89,242,443
|
|
G |
Bace1 |
beta-secretase 1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of BACE1 mRNA] |
CTD |
PMID:22484447 |
|
NCBI chr 8:50,140,092...50,162,388
Ensembl chr 8:50,139,997...50,162,361
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]; ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]; Mifepristone inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]; SH-6 compound inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]] |
CTD |
PMID:17123556 |
|
NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
ginsenoside Rg1 results in increased expression of BAX protein |
CTD |
PMID:28371286 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
ginsenoside Rg1 results in decreased expression of BCL2 protein ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of BCL2 protein] |
CTD |
PMID:26593335 PMID:28371286 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein] ginsenoside Rg1 results in increased activity of CASP3 protein |
CTD |
PMID:24386346 PMID:28371286 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
ginsenoside Rg1 results in increased activity of CASP9 protein |
CTD |
PMID:28371286 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein] |
CTD |
PMID:29964319 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions |
ISO |
ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CCNE1 protein] |
CTD |
PMID:15606011 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CDK2 protein] |
CTD |
PMID:15606011 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CDKN1A protein] |
CTD |
PMID:15606011 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP2B10 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP2B10 protein] |
CTD |
PMID:32198087 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of CYP2E1 mRNA] |
CTD |
PMID:29964319 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP3A4 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP3A4 protein] |
CTD |
PMID:32198087 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of DDIT3 protein] |
CTD |
PMID:30918470 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of ERN1 protein] |
CTD |
PMID:30918470 |
|
NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
ginsenoside Rg1 results in increased expression of FOS mRNA |
CTD |
PMID:16204943 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
ISO |
ginsenoside Rg1 results in increased expression of GCLC mRNA ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]] |
CTD |
PMID:29964319 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression multiple interactions |
ISO |
ginsenoside Rg1 results in increased expression of GCLM protein ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLM protein] |
CTD |
PMID:29964319 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Glud1 |
glutamate dehydrogenase 1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in increased expression of GLUD1 protein] |
CTD |
PMID:26593335 |
|
NCBI chr16:10,661,486...10,695,557
Ensembl chr16:10,662,021...10,695,557
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of GPT protein] |
CTD |
PMID:29964319 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]] ginsenoside Rg1 results in increased expression of HMOX1 mRNA; ginsenoside Rg1 results in increased expression of HMOX1 protein |
CTD |
PMID:25422538 PMID:29964319 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of HSPA5 protein] |
CTD |
PMID:30918470 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IFNG protein] |
CTD |
PMID:32198087 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B] ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B protein] |
CTD |
PMID:22214447 PMID:29964319 PMID:32198087 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:17655881 PMID:29964319 PMID:30918470 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
affects activity |
ISO |
ginsenoside Rg1 affects the activity of KCNH2 protein |
CTD |
PMID:15842772 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of KEAP1 protein] |
CTD |
PMID:29964319 |
|
NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
|
|
G |
Lpl |
lipoprotein lipase |
increases secretion |
ISO |
ginsenoside Rg1 results in increased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
ISO |
ginsenoside Rg1 results in increased expression of MAP2 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 9:73,204,753...73,462,965
Ensembl chr 9:73,319,710...73,462,972
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions affects phosphorylation |
ISO |
PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK1 protein] |
CTD |
PMID:22214447 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
affects phosphorylation multiple interactions |
ISO |
ginsenoside Rg1 affects the phosphorylation of MAPK3 protein PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK3 protein] |
CTD |
PMID:22214447 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:24386346 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:24386346 |
|
NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
multiple interactions increases expression |
ISO |
Mifepristone inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein]; MIR23A mRNA inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein] |
CTD |
PMID:26115870 |
|
NCBI chr 4:44,747,467...44,854,628
Ensembl chr 4:44,774,741...44,852,665
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 mRNA]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 protein] |
CTD |
PMID:26593335 |
|
NCBI chr 5:164,684,244...164,715,414
Ensembl chr 5:164,684,509...164,714,145
|
|
G |
Mir23a |
microRNA 23a |
decreases expression multiple interactions |
ISO |
ginsenoside Rg1 results in decreased expression of MIR23A mRNA Mifepristone inhibits the reaction [ginsenoside Rg1 results in decreased expression of MIR23A mRNA]; MIR23A mRNA inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein] |
CTD |
PMID:26115870 |
|
NCBI chr19:25,318,582...25,318,656
Ensembl chr19:25,318,582...25,318,656
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in decreased activity of [MTOR protein binds to RAPTOR protein]]; ginsenoside Rg1 results in increased activity of [MTOR protein binds to RAPTOR protein] |
CTD |
PMID:24386346 |
|
NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions affects localization increases expression |
ISO |
[ginsenoside Rg1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein ginsenoside Rg1 affects the localization of NFE2L2 protein [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein]] ginsenoside Rg1 results in increased expression of NFE2L2 mRNA |
CTD |
PMID:22780686 PMID:25422538 PMID:29964319 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
affects phosphorylation multiple interactions |
ISO |
ginsenoside Rg1 affects the phosphorylation of NFKBIA protein PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of NFKBIA protein] |
CTD |
PMID:22214447 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2] |
CTD |
PMID:22214447 PMID:29964319 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 protein]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]] |
CTD |
PMID:29964319 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 protein] |
CTD |
PMID:32198087 |
|
NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
|
|
G |
Pgr |
progesterone receptor |
increases expression |
ISO |
ginsenoside Rg1 results in increased expression of PGR protein |
CTD |
PMID:16204943 |
|
NCBI chr 8:7,128,656...7,187,796
Ensembl chr 8:7,128,656...7,187,796
|
|
G |
Plcg1 |
phospholipase C, gamma 1 |
multiple interactions |
ISO |
PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK1 protein]; PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK3 protein]; PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of NFKBIA protein] |
CTD |
PMID:22214447 |
|
NCBI chr 3:156,727,642...156,758,307
Ensembl chr 3:156,727,642...156,758,307
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased phosphorylation of PRKAA1 protein] |
CTD |
PMID:24386346 |
|
NCBI chr 2:54,857,688...54,893,404
Ensembl chr 2:54,857,688...54,893,404
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2] |
CTD |
PMID:22214447 PMID:29964319 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rps6 |
ribosomal protein S6 |
increases phosphorylation |
ISO |
ginsenoside Rg1 results in increased phosphorylation of RPS6 protein |
CTD |
PMID:24386346 |
|
NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
|
|
G |
Rptor |
regulatory associated protein of MTOR, complex 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in decreased activity of [MTOR protein binds to RAPTOR protein]]; ginsenoside Rg1 results in increased activity of [MTOR protein binds to RAPTOR protein] |
CTD |
PMID:24386346 |
|
NCBI chr10:108,750,620...109,058,691
Ensembl chr10:108,750,620...109,058,691
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of SIRT1 protein] |
CTD |
PMID:30918470 |
|
NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 protein] |
CTD |
PMID:32198087 |
|
NCBI chr 6:104,617,730...104,631,355
Ensembl chr 6:104,617,730...104,631,355
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
EXP ISO |
SLCO1B2 protein binds to and results in increased transport of ginsenoside Rg1 SLCO1B3 protein binds to and results in increased transport of ginsenoside Rg1 |
CTD |
PMID:25297453 |
|
NCBI chr 4:175,814,118...175,881,775
Ensembl chr 4:175,814,118...175,881,768
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SULT2A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SULT2A1 protein] |
CTD |
PMID:32198087 |
|
NCBI chr 1:76,558,721...76,614,315
Ensembl chr 1:76,252,329...76,780,230
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
ginsenoside Rg1 results in increased expression of TFF1 mRNA |
CTD |
PMID:16204943 |
|
NCBI chr20:9,892,124...9,895,984
Ensembl chr20:9,892,124...9,895,984
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF protein] |
CTD |
PMID:22214447 PMID:29964319 PMID:30918470 PMID:32198087 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 protein] |
CTD |
PMID:32198087 |
|
NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
EXP |
ginsenoside Rg2 results in increased expression of ABCC2 mRNA |
CTD |
PMID:23835644 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:28756148 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of and results in increased cleavage of CASP3 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased expression of BAX protein] |
CTD |
PMID:28756148 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased expression of BAX protein] |
CTD |
PMID:28756148 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein] |
CTD |
PMID:28756148 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of and results in increased cleavage of CASP3 protein] |
CTD |
PMID:28756148 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Crtc2 |
CREB regulated transcription coactivator 2 |
multiple interactions |
ISO |
[ginsenoside Rg2 results in increased activity of NR0B2 protein] which results in decreased activity of CRTC2 protein |
CTD |
PMID:22062806 |
|
NCBI chr 2:189,615,928...189,625,646
Ensembl chr 2:189,615,948...189,626,051
|
|
G |
G6pc3 |
glucose 6 phosphatase catalytic subunit 3 |
decreases expression multiple interactions |
ISO |
ginsenoside Rg2 results in decreased expression of G6PC3 mRNA dorsomorphin inhibits the reaction [ginsenoside Rg2 results in decreased expression of G6PC3 mRNA] |
CTD |
PMID:22062806 |
|
NCBI chr10:90,134,193...90,138,425
Ensembl chr10:90,134,193...90,138,425
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation multiple interactions |
ISO |
ginsenoside Rg2 results in increased phosphorylation of GSK3B protein [[ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] co-treated with [ginsenoside Rg2 results in increased expression of NR0B2 mRNA]] results in decreased chemical synthesis of Glucose; dorsomorphin inhibits the reaction [ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:22062806 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions increases expression increases activity |
ISO |
[[ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] co-treated with [ginsenoside Rg2 results in increased expression of NR0B2 mRNA]] results in decreased chemical synthesis of Glucose; [ginsenoside Rg2 results in increased activity of NR0B2 protein] which results in decreased activity of CRTC2 protein |
CTD |
PMID:22062806 |
|
NCBI chr 5:151,776,004...151,779,319
Ensembl chr 5:151,776,004...151,779,319
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions decreases expression |
ISO |
dorsomorphin inhibits the reaction [ginsenoside Rg2 results in decreased expression of PCK1 mRNA] |
CTD |
PMID:22062806 |
|
NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions decreases expression |
ISO |
dorsomorphin inhibits the reaction [ginsenoside Rg2 results in decreased expression of PPARGC1A mRNA] |
CTD |
PMID:22062806 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Stk11 |
serine/threonine kinase 11 |
increases phosphorylation multiple interactions |
ISO |
ginsenoside Rg2 results in increased phosphorylation of STK11 protein dorsomorphin inhibits the reaction [ginsenoside Rg2 results in increased phosphorylation of STK11 protein] |
CTD |
PMID:22062806 |
|
NCBI chr 7:12,440,751...12,457,513
Ensembl chr 7:12,440,751...12,457,513
|
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
decreases activity |
EXP |
ginsenoside Rg5 results in decreased activity of HIF1A protein |
CTD |
PMID:29298510 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Nos3 |
nitric oxide synthase 3 |
increases expression |
EXP |
ginsenoside Rg5 results in increased expression of NOS3 |
CTD |
PMID:29298510 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
Glycyrrhizic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Glycyrrhizic Acid results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
Glycyrrhizic Acid affects the reaction [1-Naphthylisothiocyanate affects the expression of ABCC3 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
multiple interactions |
ISO |
Glycyrrhizic Acid affects the reaction [1-Naphthylisothiocyanate affects the expression of ACAT2 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 1:47,972,399...47,992,654
Ensembl chr 1:47,972,399...47,992,653
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Fusaric Acid results in decreased expression of ACHE protein] |
CTD |
PMID:31150628 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:32525084 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
ALB protein binds to and affects the transport of Glycyrrhizic Acid |
CTD |
PMID:8831264 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Aqp2 |
aquaporin 2 |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Gentamicins results in decreased expression of AQP2 protein] |
CTD |
PMID:12969435 |
|
NCBI chr 7:141,237,802...141,242,837
Ensembl chr 7:141,237,768...141,245,165
|
|
G |
Aqp5 |
aquaporin 5 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [Histamine results in decreased expression of AQP5 protein] |
CTD |
PMID:29452068 |
|
NCBI chr 7:141,249,044...141,252,576
Ensembl chr 7:141,249,044...141,252,578
|
|
G |
Ar |
androgen receptor |
multiple interactions affects localization |
ISO |
Glycyrrhizic Acid binds to and results in increased activity of AR protein Glycyrrhizic Acid affects the localization of AR protein |
CTD |
PMID:28478275 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Fusaric Acid results in decreased expression of BDNF protein] |
CTD |
PMID:31150628 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Casp2 |
caspase 2 |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene results in increased activity of CASP2 protein] |
CTD |
PMID:22051199 |
|
NCBI chr 4:71,652,358...71,670,228
Ensembl chr 4:71,652,354...71,670,239
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene results in increased activity of CASP3 protein]; Glycyrrhizic Acid inhibits the reaction [Fusaric Acid results in decreased expression of CASP3 protein] |
CTD |
PMID:22051199 PMID:31150628 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp6 |
caspase 6 |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene results in increased activity of CASP6 protein] |
CTD |
PMID:22051199 |
|
NCBI chr 2:235,341,326...235,353,715
Ensembl chr 2:235,341,365...235,353,967 Ensembl chr 2:235,341,365...235,353,967
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene results in increased activity of CASP8 protein] |
CTD |
PMID:22051199 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene results in increased activity of CASP9 protein] |
CTD |
PMID:22051199 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [Cyclosporine results in increased expression of CCL2 mRNA] |
CTD |
PMID:27585667 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [Histamine results in decreased phosphorylation of CREB1 protein] |
CTD |
PMID:29452068 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
decreases expression |
EXP |
Glycyrrhizic Acid results in decreased expression of CYP11B2 mRNA |
CTD |
PMID:10474021 PMID:11798659 |
|
NCBI chr 7:116,155,928...116,161,781
Ensembl chr 7:116,156,219...116,255,167
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases expression multiple interactions |
ISO |
Glycyrrhizic Acid results in increased expression of CYP3A4 mRNA; Glycyrrhizic Acid results in increased expression of CYP3A4 protein Glycyrrhizic Acid results in increased expression of CYP3A11 mRNA NR1I2 protein affects the reaction [Glycyrrhizic Acid results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:22982774 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression multiple interactions |
ISO |
Glycyrrhizic Acid results in decreased expression of CYP7A1 mRNA Glycyrrhizic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP7A1 mRNA] |
CTD |
PMID:22982774 PMID:28549656 |
|
NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene results in decreased activity of EPHX2 protein] |
CTD |
PMID:22051199 |
|
NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
Glycyrrhizic Acid inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with BCG Vaccine] results in increased activity of GPT protein] Glycyrrhizic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased activity of GPT protein] |
CTD |
PMID:19196740 PMID:28549656 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Hmgb1 |
high mobility group box 1 |
decreases secretion multiple interactions decreases activity |
ISO EXP |
Glycyrrhizic Acid results in decreased secretion of HMGB1 protein Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased expression of HMGB1 protein] Glycyrrhizic Acid results in decreased activity of HMGB1 protein |
CTD |
PMID:27585667 PMID:27689324 PMID:27783111 PMID:32525084 |
|
NCBI chr12:7,082,529...7,090,246
Ensembl chr16:37,500,017...37,502,237
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Glycyrrhizic Acid promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 mRNA]; Glycyrrhizic Acid promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 protein] |
CTD |
PMID:17917259 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
decreases expression |
EXP |
Glycyrrhizic Acid results in decreased expression of HSD11B2 mRNA |
CTD |
PMID:10474021 PMID:11798659 |
|
NCBI chr19:37,476,083...37,481,326
Ensembl chr19:37,476,095...37,481,307
|
|
G |
Ifng |
interferon gamma |
affects expression |
ISO |
Glycyrrhizic Acid affects the expression of IFNG mRNA |
CTD |
PMID:16945185 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
[Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased expression of [IL12A protein binds to IL12B protein]; [Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased expression of IL12A mRNA |
CTD |
PMID:11412311 |
|
NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
[Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased expression of [IL12A protein binds to IL12B protein]; [Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased expression of IL12B mRNA; [Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased expression of IL12B protein |
CTD |
PMID:11412311 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein] Glycyrrhizic Acid inhibits the reaction [Histamine results in increased expression of IL6 mRNA]; Glycyrrhizic Acid inhibits the reaction [Histamine results in increased secretion of IL6 protein] Glycyrrhizic Acid inhibits the reaction [Chlorpyrifos results in increased expression of IL6 mRNA]; Glycyrrhizic Acid inhibits the reaction [Chlorpyrifos results in increased expression of IL6 protein] |
CTD |
PMID:21644799 PMID:26524701 PMID:29452068 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
EXP |
[Glycyrrhizic Acid co-treated with bafilomycin A1] results in increased lipidation of MAP1LC3B protein; Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased expression of and results in increased lipidation of MAP1LC3B protein]; Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:32525084 |
|
NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [Picryl Chloride results in increased secretion of MMP2 protein] |
CTD |
PMID:16945185 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Doxorubicin results in increased phosphorylation of MTOR protein] |
CTD |
PMID:32525084 |
|
NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of MTTP mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 2:243,366,181...243,407,608
Ensembl chr 2:243,366,181...243,407,608
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [Histamine results in increased expression of MUC5AC mRNA]; Glycyrrhizic Acid inhibits the reaction [Histamine results in increased secretion of MUC5AC protein] |
CTD |
PMID:29452068 |
|
NCBI chr 1:214,725,482...214,756,653
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased activity of [NFKB1 protein binds to RELA protein] |
CTD |
PMID:11412311 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [Histamine results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:29452068 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 mRNA]; Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein] |
CTD |
PMID:17917259 PMID:21644799 PMID:23373965 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of NPC1L1 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr14:86,345,946...86,560,694
Ensembl chr14:86,345,953...86,560,694
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression |
ISO |
Glycyrrhizic Acid results in increased expression of NR0B2 mRNA |
CTD |
PMID:22982774 |
|
NCBI chr 5:151,776,004...151,779,319
Ensembl chr 5:151,776,004...151,779,319
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
Glycyrrhizic Acid results in increased activity of NR1I2 protein NR1I2 protein affects the reaction [Glycyrrhizic Acid results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:22982774 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Pik3cd |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta |
decreases activity |
ISO |
Glycyrrhizic Acid results in decreased activity of PIK3CD protein |
CTD |
PMID:21644799 |
|
NCBI chr 5:166,602,053...166,628,028
Ensembl chr 5:166,602,053...166,628,028
|
|
G |
Pik3cg |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma |
decreases activity |
ISO |
Glycyrrhizic Acid results in decreased activity of PIK3CG protein |
CTD |
PMID:21644799 |
|
NCBI chr 6:51,465,696...51,501,234
Ensembl chr 6:51,465,908...51,498,337
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 mRNA]; Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein] |
CTD |
PMID:17917259 PMID:21644799 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
[Glycyrrhizic Acid co-treated with Lipopolysaccharides] results in increased activity of [NFKB1 protein binds to RELA protein] Glycyrrhizic Acid inhibits the reaction [Histamine results in increased phosphorylation of RELA protein] Glycyrrhizic Acid inhibits the reaction [Benzo(a)pyrene affects the localization of RELA protein]; Glycyrrhizic Acid inhibits the reaction [Chlorpyrifos results in increased phosphorylation of RELA protein] |
CTD |
PMID:11412311 PMID:22051199 PMID:26524701 PMID:29452068 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Ren |
renin |
decreases activity |
ISO |
Glycyrrhizic Acid results in decreased activity of REN protein |
CTD |
PMID:20460744 |
|
NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Glucose results in decreased expression of SIRT1 protein] |
CTD |
PMID:25162824 |
|
NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
|
|
G |
Slc51b |
solute carrier family 51 subunit beta |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SLC51B mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 8:70,930,196...70,938,559
Ensembl chr 8:70,930,347...70,932,986
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SLCO1A4 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 4:175,969,549...176,026,227
Ensembl chr 4:175,969,549...176,026,163
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Glucose results in decreased expression of SOD2 protein] |
CTD |
PMID:25162824 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
EXP |
Glycyrrhizic Acid affects the reaction [Doxorubicin results in increased expression of SQSTM1 protein] |
CTD |
PMID:32525084 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
Glycyrrhizic Acid inhibits the reaction [Glucose results in increased expression of TGFB1 protein] |
CTD |
PMID:25162824 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [Glucose results in decreased expression of TJP1 protein]; Glycyrrhizic Acid inhibits the reaction [Palmitic Acid results in decreased expression of TJP1 protein] |
CTD |
PMID:27689324 PMID:27783111 |
|
NCBI chr 1:126,146,489...126,515,359
Ensembl chr 1:126,146,489...126,227,469
|
|
G |
Tjp2 |
tight junction protein 2 |
multiple interactions |
ISO |
Glycyrrhizic Acid inhibits the reaction [Glucose results in decreased expression of TJP2 protein]; Glycyrrhizic Acid inhibits the reaction [Palmitic Acid results in decreased expression of TJP2 protein] |
CTD |
PMID:27689324 PMID:27783111 |
|
NCBI chr 1:241,945,816...242,084,044
Ensembl chr 1:241,945,841...242,083,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF mRNA]; Glycyrrhizic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Glycyrrhizic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein] Glycyrrhizic Acid inhibits the reaction [Chlorpyrifos results in increased expression of TNF mRNA]; Glycyrrhizic Acid inhibits the reaction [Chlorpyrifos results in increased expression of TNF protein] |
CTD |
PMID:17917259 PMID:21644799 PMID:26524701 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
alpha-hederin inhibits the reaction [[Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 enhancer]] which results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:10378784 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases expression decreases activity |
ISO |
alpha-hederin inhibits the reaction [[Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 enhancer]] which results in increased expression of CYP1A1 mRNA]; alpha-hederin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of and results in increased activity of CYP1A1 protein]; alpha-hederin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] alpha-hederin results in decreased expression of CYP1A1 mRNA alpha-hederin results in decreased activity of CYP1A1 protein |
CTD |
PMID:9861456 PMID:10378784 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity decreases expression |
ISO |
alpha-hederin results in decreased activity of CYP1A2 protein alpha-hederin results in decreased expression of CYP1A2 mRNA |
CTD |
PMID:9861456 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases expression |
ISO |
alpha-hederin results in decreased expression of CYP2B1 mRNA |
CTD |
PMID:9861456 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
ISO |
alpha-hederin results in decreased activity of CYP2E1 protein |
CTD |
PMID:9861456 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases activity |
ISO |
madecassoside results in decreased activity of CYP2C19 protein |
CTD |
PMID:21349323 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases activity |
ISO |
madecassoside results in decreased activity of CYP3A4 protein |
CTD |
PMID:21349323 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
increases transport |
EXP ISO |
ABCB11 protein results in increased transport of notoginsenoside R1 |
CTD |
PMID:25297453 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression multiple interactions |
ISO |
notoginsenoside R1 results in increased expression of ABCB1 mRNA notoginsenoside R1 results in increased expression of ABCB1A mRNA NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of ABCB1 mRNA] |
CTD |
PMID:25472953 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases transport |
ISO |
ABCC1 protein results in increased transport of notoginsenoside R1 |
CTD |
PMID:25297453 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases transport |
EXP ISO |
ABCC2 protein results in increased transport of notoginsenoside R1 |
CTD |
PMID:25297453 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases transport |
EXP ISO |
ABCG2 protein results in increased transport of notoginsenoside R1 |
CTD |
PMID:25297453 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in decreased abundance of Glutathione]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in decreased expression of MIR20A mRNA]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Triglycerides]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IFNG protein]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL2 protein]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR126A mRNA]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR21A mRNA]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of TNF protein] |
CTD |
PMID:24933211 |
|
NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO EXP |
notoginsenoside R1 inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of APP protein modified form] notoginsenoside R1 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK8 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:24975829 PMID:25714973 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Atp5f1d |
ATP synthase F1 subunit delta |
multiple interactions |
EXP |
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein] |
CTD |
PMID:25305180 |
|
NCBI chr 7:12,426,807...12,432,120
Ensembl chr 7:12,426,809...12,432,130
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Excitatory Amino Acid Agonists results in increased expression of BAX protein] MIR26A1 mRNA affects the reaction [notoginsenoside R1 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of BAX protein]]; notoginsenoside R1 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of BAX protein] notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased expression of BAX protein] |
CTD |
PMID:19224577 PMID:24975829 PMID:25305180 PMID:31158334 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein] MIR26A1 mRNA affects the reaction [notoginsenoside R1 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased expression of BCL2 protein]]; notoginsenoside R1 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased expression of BCL2 protein] notoginsenoside R1 results in increased expression of BCL2 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of BCL2 protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein] |
CTD |
PMID:19224577 PMID:20023602 PMID:23170834 PMID:24975829 PMID:25305180 PMID:31158334 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of BGLAP mRNA] |
CTD |
PMID:26362186 |
|
NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of BID protein modified form] |
CTD |
PMID:23170834 |
|
NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CASP3 protein modified form] MIR26A1 mRNA affects the reaction [notoginsenoside R1 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased cleavage of CASP3 protein]]; notoginsenoside R1 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased cleavage of CASP3 protein] 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein] |
CTD |
PMID:23170834 PMID:24437944 PMID:24720662 PMID:24975829 PMID:25305180 PMID:25738436 PMID:31158334 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP8 protein] |
CTD |
PMID:23170834 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP9 protein] |
CTD |
PMID:23170834 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased activity of CAT protein] |
CTD |
PMID:25503068 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein] |
CTD |
PMID:23170834 PMID:25472953 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Chat |
choline O-acetyltransferase |
increases expression |
ISO |
notoginsenoside R1 results in increased expression of CHAT |
CTD |
PMID:25714973 |
|
NCBI chr16:8,576,858...8,686,131
Ensembl chr16:8,577,840...8,686,131
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of CHUK protein modified form] |
CTD |
PMID:25472953 |
|
NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
EXP |
notoginsenoside R1 results in decreased activity of CYP1A2 protein |
CTD |
PMID:25834921 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases expression |
ISO |
notoginsenoside R1 results in increased expression of CYP3A4 mRNA notoginsenoside R1 results in increased expression of CYP3A11 mRNA |
CTD |
PMID:25472953 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases expression |
ISO EXP |
notoginsenoside R1 results in increased phosphorylation of and results in increased activity of ESR1 protein notoginsenoside R1 results in increased expression of ESR1; notoginsenoside R1 results in increased expression of ESR1 mRNA; notoginsenoside R1 results in increased expression of ESR1 protein [1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole results in decreased activity of ESR1 protein] which results in decreased susceptibility to notoginsenoside R1; [notoginsenoside R1 co-treated with Lipopolysaccharides] results in increased expression of ESR1 protein; fulvestrant inhibits the reaction [[notoginsenoside R1 co-treated with Lipopolysaccharides] results in increased expression of ESR1 protein] |
CTD |
PMID:23170834 PMID:24720662 PMID:25738436 PMID:26362186 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esr2 |
estrogen receptor 2 |
increases expression |
EXP |
notoginsenoside R1 results in increased expression of ESR2 |
CTD |
PMID:24720662 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of F3 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of F3 protein] |
CTD |
PMID:9102164 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of FAS mRNA] |
CTD |
PMID:23170834 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased secretion of FN1 protein]; notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased expression of FN1 mRNA]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of FN1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of FN1 mRNA] |
CTD |
PMID:16632126 |
|
NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
EXP |
Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; Dactinomycin inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide results in increased expression of GCLC protein] |
CTD |
PMID:24437944 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
multiple interactions |
ISO |
[GRIN1 protein co-treated with GRIN2B protein] results in increased susceptibility to notoginsenoside R1 |
CTD |
PMID:19224577 |
|
NCBI chr 3:2,507,745...2,534,664
Ensembl chr 3:2,506,896...2,534,663
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
ISO |
[GRIN1 protein co-treated with GRIN2B protein] results in increased susceptibility to notoginsenoside R1 |
CTD |
PMID:19224577 |
|
NCBI chr 4:169,541,620...170,000,216
Ensembl chr 4:169,560,387...169,999,873
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases expression |
ISO EXP |
fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of GSK3B protein modified form]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of GSK3B protein modified form]; wortmannin inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of GSK3B protein modified form]] notoginsenoside R1 results in increased expression of GSK3B protein modified form |
CTD |
PMID:23170834 PMID:24720662 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein notoginsenoside R1 results in increased expression of HMOX1; notoginsenoside R1 results in increased expression of HMOX1 protein Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide results in increased expression of HMOX1 protein] |
CTD |
PMID:24437944 PMID:24720662 PMID:25422538 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] |
CTD |
PMID:23170834 PMID:25472953 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Ide |
insulin degrading enzyme |
multiple interactions increases expression |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [notoginsenoside R1 results in increased expression of IDE] |
CTD |
PMID:25714973 |
|
NCBI chr 1:255,914,465...256,014,168
Ensembl chr 1:255,914,447...256,013,495
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IFNG protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG protein] |
CTD |
PMID:23170834 PMID:24933211 PMID:25472953 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IKBKB protein modified form] |
CTD |
PMID:25472953 |
|
NCBI chr16:74,177,233...74,230,809
Ensembl chr16:74,177,215...74,230,815
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
notoginsenoside R1 promotes the reaction [Lipopolysaccharides results in increased expression of IL10 protein] |
CTD |
PMID:23170834 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il15 |
interleukin 15 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL15 mRNA] |
CTD |
PMID:25472953 |
|
NCBI chr19:23,542,606...23,624,366
Ensembl chr19:23,542,889...23,554,594
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1A mRNA] |
CTD |
PMID:25472953 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] MIR26A1 mRNA affects the reaction [notoginsenoside R1 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B mRNA]]; MIR26A1 mRNA affects the reaction [notoginsenoside R1 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B protein]]; notoginsenoside R1 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B mRNA]; notoginsenoside R1 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B protein] 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; Fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] |
CTD |
PMID:23170834 PMID:25472953 PMID:25738436 PMID:31158334 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL2 protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL2 mRNA] |
CTD |
PMID:24933211 PMID:25472953 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL6 protein] MIR26A1 mRNA affects the reaction [notoginsenoside R1 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 mRNA]]; MIR26A1 mRNA affects the reaction [notoginsenoside R1 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 protein]]; notoginsenoside R1 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 protein] 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; Fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:17655881 PMID:23170834 PMID:24933211 PMID:25472953 PMID:25738436 PMID:31158334 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Ilk |
integrin-linked kinase |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Streptozocin results in increased activity of ILK protein] |
CTD |
PMID:25503068 |
|
NCBI chr 1:170,578,941...170,585,192
Ensembl chr 1:170,578,889...170,585,189
|
|
G |
Itga3 |
integrin subunit alpha 3 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 mRNA]; notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 protein]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGA3 mRNA]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGA3 protein] |
CTD |
PMID:25503068 |
|
NCBI chr10:82,855,841...82,887,755
Ensembl chr10:82,855,613...82,887,497
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGAM protein] |
CTD |
PMID:17655881 |
|
NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGB1 mRNA]; notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGB1 protein]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGB1 mRNA]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGB1 protein] |
CTD |
PMID:25503068 |
|
NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
|
|
G |
Itgb2 |
integrin subunit beta 2 |
decreases expression multiple interactions |
ISO EXP |
notoginsenoside R1 results in decreased expression of ITGB2 protein notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGB2 protein] |
CTD |
PMID:17655881 PMID:18176958 |
|
NCBI chr20:11,777,773...11,815,647
Ensembl chr20:11,777,783...11,815,647
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein] fulvestrant inhibits the reaction [notoginsenoside R1 results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of MAPK1 mRNA]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:16458614 PMID:16632126 PMID:24437944 PMID:24975829 PMID:25004876 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP
|